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Abstract 
Pterocellin A is a novel bioactive alkaloid isolated from the New Zealand marine 
bryozoan Pterocella vesiculosa. It exhibits potent antitumour activity towards the 
P388 (murine leukaemia) cell line in vitro with an IC50 value of 477 ng/mL. 
Further screening at the NCI indicated that it was selectively sensitive towards 
certain non-small cell lung, melanoma, and breast cancer cell lines, however, the 
biological mode of action of pterocellin A is unknown.  
This project investigated and elucidated the cytotoxicity of pterocellin A using the 
human cervical cancer cell line HeLa. Cellular toxicity can be manifested as either 
necrotic or apoptotic cell death. Cancer cells are prone to resisting apoptosis, and 
one of the key mechanisms recognised in anticancer agents is the induction of 
apoptosis. Pterocellin A exhibited similar cytotoxicity against the HeLa cell line 
compared to P388 cells with an IC50 value of 886 ng/mL. In this study, HeLa cells 
were incubated with various concentrations (up to 2000 ng/mL) of pure 
pterocellin A, and characteristic markers of apoptotic and necrotic cell death were 
investigated using several in vitro biochemistry techniques. Assessments were 
made on the morphological and biochemical changes in HeLa cells after treatment 
with pterocellin A.  
Time-course MTT and LDH assays were carried out and the results showed that 
only a low level of cytosolic LDH was detected in the supernatant after all the 
cells had died from pterocellin A treatment at 2000 ng/mL. This indicated the 
cells maintained membrane integrity upon death which suggested apoptosis. 
Additionally, morphological changes were observed under the microscope after 
six hours of treatment. Cell shrinkage and nucleus condensation were observed, as 
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well as apparent membrane blebbing, a key feature of apoptosis. The MTT data 
were also indicative of mitochondria impairment which could suggest that 
pterocellin A targets the mitochondria. This idea was supported by the observed 
changes in the morphology and location of the mitochondria after exposure to 
pterocellin A. Furthermore, the level of activated caspase-3 in HeLa cells 
increased after treatment with pterocellin A; activated caspase-3 can only be 
detected after a series of signalling events following the induction of apoptosis. 
These data support the notion that pterocellin A is an inducer of apoptosis in 
HeLa cells.  
This project also utilised the biochemical assays to develop a systematic bioassay 
screening system at the University of Waikato, and further investigated the 
bioactive metabolites of P. vesiculosa. The same approach taken to study pure 
pterocellin A in HeLa cells was successfully applied to the bioassay development. 
The bioactive fractions separated from the crude extract were analysed by LC-MS 
and several unknown metabolites were observed, however due to time constraints 
associated with the project, no further investigation was carried out. 
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1 
1. Literature Review and Research Aims 
1.1 Natural Products 
Natural products, also known as secondary metabolites, are organic compounds 
produced by living organisms. Unlike primary metabolites such as carbohydrates 
and amino acids, secondary metabolites are considered non-essential to life and 
have no apparent function within the organism.1 These compounds attract 
research interest because they can exert physiological effects on other organisms, 
often playing an ecological role in regulating a wide range of chemical 
interactions. These include pheromone chemical communication, chemical 
defence mechanisms, and mutualistic interactions between plants, 
microorganisms, insects and animals.2 Natural products are known for their 
characteristic chemical diversity, novelty and structural complexity, often 
containing unusual combinations of functional groups which attribute to 
biochemical specificity and other molecular properties.3 Many bioactive 
compounds have been found to have therapeutic effects in humans. These 
properties thus make natural products ideal candidates for lead compounds in drug 
discovery in the pharmaceutical industry. 
Historic uses of terrestrial organisms for medicinal purposes prompted early work 
in natural product studies.4 Traditionally, the extensive screening of natural 
products has been largely focused on terrestrial environments, with many of the 
known natural products isolated from higher plants and microorganisms.5 Some of 
the most well-known drugs are derived from terrestrial sources such as morphine 
and aspirin (Figure 1.1). Morphine was isolated from the opium poppy in 1806 
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and this small molecule led to the development of pain medicine and an 
understanding of the pain receptor pathways.6 Aspirin, discovered in 1897, is a 
synthetic derivative of salicin, a natural product found in the bark of the willow 
tree.6  
    
Figure 1.1 (A). Structure of morphine. (B). Structure of aspirin. 
However, the rate of discovery of novel bioactive compounds from terrestrial 
organisms has decreased in recent years, due to an increased frequency of 
rediscovery.5 This led to the search being extended to unexplored habitats in 
marine environments. The marine environment is a rich source of biological and 
chemical biodiversity. The ocean covers greater than 70% of the earth’s surface 
but the chemical resources from this environment are largely untapped.7 Thirty 
two of the thirty three animal phyla are represented in aquatic environments and 
fifteen phyla are exclusive to the marine environment.8 Potential pharmaceutical 
leads from natural products are likely to be found in places with high biodiversity, 
such as the ocean fringe or coral reefs in marine environments.9 Marine natural 
products are often produced in sessile, colonial marine species such as soft-bodied 
invertebrates including sponges, bryozoans, and tunicates. These organisms, 
living in such a highly competitive environment, have evolved to overcome the 
ecological pressure to compete for space with surrounding species and to evade 
A B 
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predators.10 Due to their lack of movement and physical defence structures, it is 
thought that these organisms survive by utilising natural products as chemical 
defence mechanisms.11 The compounds produced in the marine environment are 
unique from their terrestrial counterpart. Differences in the environments such as 
food chain and available nutrients meant that the classes of compounds produced 
are vastly different, with the presence of halogenated compounds being a frequent 
occurrence in the marine environment.11 Therefore the marine environment 
represents a great place to explore natural products for pharmaceutical potential. 
With advanced diving technology and greater accessibility, marine biodiversity is 
attracting increasing attention for this type of research. 
 
1.2 Biology of Bryozoans 
Bryozoans, commonly known as sea moss or moss animals, are sedentary, filter-
feeding invertebrates found in aquatic environments. There are over 8000 species 
of bryozoans described, many more were observed in fossil records.12 Most 
species inhabit marine environments with very few in freshwater lakes and 
rivers.13 The phylum Bryozoa, also known as Ectoprocta, is made up of three 
classes: Gymnolaemata, Phylactolaemata, and Stenolaemata; Phylactolaemata 
consists of species that are exclusively marine.13 Currently there are just under 
1000 species found in and around New Zealand, of which the vast majority are 
marine species.14  
Bryozoans can be found in a variety of marine habitats due to their sessile nature. 
These include coral reefs and rocks, as well as man-made environments such as 
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on the bottom of ships. Bryozoans are colonial animals; forming colonies made up 
of large numbers of intercommunicating individuals termed zooids.13 A zooid 
body plan consists of two parts, the polypide and the cystid (Figure 1.2). Although 
zooids vary in shape and the detail of their structures, the basic body plan has little 
variation between species.13 Colonies of bryozoans grow typically by asexual 
reproduction; a single zooid can reproduce itself to form genetically identical 
textured formations with a variety of external morphology.12 Being sessile filter 
feeders, bryozoans collect food from the surrounding water via a circle of ciliated 
post-oral tentacles (the lophophore) covered by the epistome. Due to their small 
size, bryozoans have no respiratory or circulatory system.13 
 
 
Figure 1.2 Zooid structure (adapted from Reference 12).12 
(A). Body plan of a zooid. (B). Internal anatomy of a 
freshwater bryozoan Fredericella. (Marine species share 
the same anatomy) 
 
A B 
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1.3 Bioactive Natural Products from Marine Bryozoans 
Much of the research on marine natural products has been focused on the phyla 
Porifera and Cnidaria, with little investigation into Bryozoa. Bryozoans are of 
particular research interest due to the variety of secondary metabolites they 
contain. A number of novel natural products from bryozoans have been isolated to 
date. These have been extensively reviewed including in the annual reviews in 
Natural Products Reports detailing marine natural products classified by 
phylum.5, 15-43 A discussion of selected literature focusing on bioactive natural 
products from bryozoans is presented here. 
The best-known examples of bioactive bryozoan metabolites are the bryostatins, a 
class of structurally related compounds originally isolated from the marine 
bryozoan Bulgula neritina.44 To date, 20 bryostatins have been identified and one 
more noted bryostatin is yet to be identified.44-56 The bryostatins share a common, 
complex macrolide ring structure with various substituents. This ring structure has 
been given the name bryopyran (Figure 1.3).45 
 
Figure 1.3 Bryopyran ring system.45 
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The first compound of the family, bryostatin 1 (1), was isolated from an extract of 
B. neritina obtained from the Gulf of Mexico in 1968. The structure was 
elucidated and published in 1982 by Pettit et al. It was found to have notable 
antineoplastic activity with an ED50 of 0.89 μg/mL against the P388 murine 
leukaemia cell line.44 The structures of bryostatin 2 (2) and bryostatin 3 (3) were 
obtained from B. neritina collected from the eastern Pacific Ocean and published 
in the following year.45-46  
 
(1) 
  
 
(2) 
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Over the next 20 years, further bryostatins were isolated from B. neritina sourced 
from various locations and possessed similar bioactivities comparable to 
bryostatin 1. The isolation process was directed by bioactivity screening of the 
fractions, and the structural elucidation was achieved by a number of methods 
including high performance liquid chromatography (HPLC), liquid 
chromatography-mass spectrometry (LC-MS), one and two-dimensional 1H and 
13C nuclear magnetic resonance (NMR) spectroscopy, and X-ray diffraction 
techniques.  
Bryostatins 4 (4) – 18 (18) were isolated from extracts collected from the Gulfs of 
Mexico, California, and Sagami; bryostatins 19 (19) and 20 (20) were from the 
South China Sea and the east coast of America respectively.47-56 
(3) 
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(4) R1 = B; R2 = C (5) R1 = -H; R2 = C 
(6) R1 = A; R2 = C (7) R1 = -H; R2 = A 
(8) R1 = A; R2 = B (9) R1 = E; R2 = B 
(10) R1, R2 =A (11) R1 =  -H; R2 = B 
(12) R1, R2 = B (13) R1= -OH; R2 = D 
(14) R1 = A; R2 = B (15) R1 = F; R2 = A 
 
A =  B =  C=  
D =   E =  
F =  
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(16) R1 = -H; R2 = CO2CH3 
(17) R1 = CO2CH3; R2 = -H 
 
 
 
(19) R = CO2(CH2)2CH3 
(20) R = -H 
(18) 
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For many years, it was thought that the bryostatins were produced by B. neritina 
due to their isolation from a diverse distribution of bryostatins in different 
geographical locations. However, all but one bryostatin were isolated from B. 
neritina; bryostatin 8 was isolated from the species Amanthia convoluta.48 
Questions were raised about the origin of the bryostatins as to whether they were 
produced endogenously, sequestered through diet, or perhaps the result of a 
bacterial symbiotic relationship. Studies have shown that antibiotic treated B. 
neritina had reduced levels of bryostatins, which supported the theory of a 
bacterial symbiotic relationship.57 In 2004, Lopanik et al. demonstrated for the 
first time the symbiotic relationship between the bacterium Endobugula sertula 
and B. neritina.58 Treatments of antibiotic gentamicin were applied to B. neritina 
larvae since the larvae possess much higher concentrations of bryostatins than the 
adults. The untreated larvae were highly unpalatable to pinfish, reducing their 
consumption of food pellets by 80%. In contrast, antibiotic treated larvae only 
decreased the feeding consumption of the pinfish by 20%. It was found that the 
larvae with antibiotic-knockout of E. sertula significantly lacked bryostatin 
production compared to the control. Also, the extract of larvae from Delaware B. 
cf. neritina contained no bryostatins. Interestingly Delaware B. cf. neritina larvae 
do not possess E. sertula. This further supported the notion that the production of 
bryostatins was due to bacterial symbionts.56, 58 
There have been a number of studies on the bryostatins and their biological 
activity but bryostatin 1 is by far the most studied compound of its class. 
Bryostatin 1 has been shown to have antitumour and immune stimulation 
properties. It inhibits tumour growth in vitro and in vivo as well as the inhibition 
of tumour invasion and angiogenesis.59 It has been found that bryostatin 1 
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interacts with the enzyme protein kinase C (PKC), a family of serine/threonine 
kinases that play important roles in cell signalling. Bryostatin 1 can bind to the 
regulatory domain of the PKC with a binding affinity of 1.35±0.17x10-9 M and 
competes with the natural PKC ligands such as phorbol esters.60 Although binding 
of phorbol ester to PKC promotes tumour growth, bryostatin 1 produces an 
antineoplastic effect. Initial short-term incubation with bryostatin 1 induces 
activation of PKC by autophosphorylation and translocation to the cell membrane, 
whilst long-term exposure leads to ubiquitination of PKC and subsequent 
degradation and therefore significant down-regulation of the PKC pathway. 
Bryostatin 1 has been in over thirty phase I and II clinical trials for a variety of 
cancers such as myeloid leukaemia, melanoma, lymphocytic leukaemia, non-
Hodgkin’s lymphoma, metastatic myeloma, relapsed lymphoma, chronic 
lymphocytic leukaemia and non-small cell lung cancer.11, 61 As a single agent, 
bryostatin 1 only had minimal effects in phase II trials and did not progress to 
phase III as a cancer treatment; it did however show improved results in 
combination with other chemotherapeutic agents in potentiating pro-apoptotic 
effects.11, 61 More recently, the clinical applications of bryostatin 1 have been 
explored in areas other than cancer, current clinical trials are in progress for 
Alzheimer’s disease and HIV.61  
Another bryostatin was recently found to induce apoptosis in acute monocytic 
leukaemia cells both in vitro and in vivo, as well as in primary U937 cells.62 
Bryostatin 5 inhibited tumour growth (IC50 10.71±72.11 nM) and induced 
apoptosis through upregulated modulator of apoptosis (PUMA), a decrease in the 
mitochondrial membrane potential, and the activation of p53, a tumour suppressor 
protein. The cells displayed distinct morphological characteristics of apoptosis 
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using transmission electron microscopy. Bryostatin 5 also significantly decreased 
the expression of anti-apoptotic protein Bcl-XL and increased the expression of 
pro-apoptotic proteins such as the Bcl-2 associated X protein (BAX), Bcl-2 
antagonist killer 1 (BAK), cleaved caspase-9 and cleaved caspase-3.62 This 
finding might facilitate clinical development of bryostatin 5 for the treatment of 
acute monocytic leukaemia. 
There have been other novel bioactive compounds isolated from bryozoans, 
although unlike the bryostatins, the biological mechanisms of action are often 
unknown. However, due to their excellent anticancer/antimicrobial activity, they 
have the potential to be used as lead compounds for pharmaceutical research. 
Caulibugulones A – F (21) – (24) are a group of six novel alkaloids isolated from 
Calibugula intermis collected in the south Pacific near Palau.63 The isolation 
process was guided by bioassay. Final isolation and structural elucidation of the 
metabolites was achieved by HPLC, positive-ion fast-atom bombardment mass 
spectrometry (FABMS), and NMR spectroscopy.  
All caulibugulone alkaloids displayed cytotoxicity against the murine IC-2WT 
tumour cell line in vitro (Table 1.1). The mode of action is not fully understood. 
One group proposed that the caulibugulones are selective inhibitors of the Cdc25 
family of cell cycle-controlling protein phosphatases.64 It was demonstrated in 
vitro that caulibugulone A could irreversibly bind to Cdc25B protein in HeLa 
cells. This binding interaction directly inhibited the Cdc25B activity, generated 
reactive oxygen species, and consequently led to cell arrest at both G1 and G2/M 
phases of the cell cycle.64  
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(21)  R1 = -H; R2 = -CH3 (22)  R = -H 
(23)  R1 = -Br; R2 = -CH3 (24)  R = -CH2CH2OH 
(25)  R1 = -Cl; R2 = -CH3   
(26)  R1 = -H; R2 = -CH2CH2OH   
 
Table 1.1 IC50 values of caulibugulones A–F against the murine IC-2WT cell line.63 
Compound IC50 (μg/mL) 
Caulibugulone A 0.34 
Caulibugulone B 0.22 
Caulibugulone C 0.28 
Caulibugulone D 1.67 
Caulibugulone E 0.03 
Caulibugulone F 0.10 
 
Four novel bioactive polyketide-derived metabolites, myriaporones 1 – 4 (27) – 
(30) were isolated form Myriapora truncata collected from the Western 
Mediterranean Sea.65 Myriaporones 1 and 2 were active against murine leukaemia 
L1210 cells (99% inhibition at 50 μg/mL, 87% inhibition at 25 μg/mL). The 
isolation of myriaporones 3 and 4 proved to be difficult due to being in 
inseparable equilibrium as interconverting isomers. The bioactivity of the mixture 
was analysed and displayed 88% growth inhibition at 0.20 μg/mL.65 
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Eusynstyelamides are tryptophan-derived compounds originally isolated from the 
ascidian Eusynstyela latericius.66 Four novel eusynstyelamides, ent-
eusynstyelamide B (31), and eusynstyelamides D – F (32) – (34) have also been 
isolated from the Arctic bryozoan Tegella cf. spitzbergensis.67 Ent-
eusynstyelamide B is an enantiomer of the previously published eusynstyelamide 
B. These four eusynstyelamides exhibited antimicrobial activities with minimum 
inhibitory concentration (MIC) values against various bacteria listed in Table 1.2. 
Eusynstyelamides D and E also displayed weak activity against the melanoma cell 
line A-2058 with IC50 values of 57 μM and 114.3 μM respectively.67 
 
(27) (28) 
(29) (30) 
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Table 1.2 Antibacterial activities of Eusynstyelamides isolated from the Arctic bryozoan 
Tegella cf. spitzbergensis.67 
 MIC  (μg/mL) 
 Ent-B D E F 
Staphylococcus aureus 6.25 12.5 12.5 6.25 
Escherichia coli 12.5 12.5 12.5 12.5 
Pseudomonas aeruginosa 25 25 25 12.5 
Corynebacterium glutamicum 12.5 12.5 12.5 6.25 
Methicillin-resistant 
Staphylococcus aureus 
20 20 20 >50 
 
 
 
 
 
(31) 
(32) 
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Pterocellins are a class of novel alkaloids isolated from the marine bryozoan 
Pterocella vesiculosa collected off the coast of the North Island, New Zealand. 
The isolation and structural elucidation of these compounds was achieved using 
various chromatographic and analytical techniques. The extracts were 
characterised using LC-MS and isolation and purification were also guided by 
bioactivity (cell viability) assays (carried out at the University of Canterbury). The 
structures of the compounds were elucidated using NMR spectroscopy and 
confirmed by single-crystal X-ray diffraction of pterocellin A.68-69  
(33) 
(34) 
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Bioactivity testing of two pterocellins A (35) and B (36) indicated promising 
antibacterial, antitumour, and antifungal activities.68 It was found that pterocellins 
A and B were active against the P388 murine leukaemia cell line (IC50 values 477 
and 323 ng/mL, respectively); the bacterium Bacillus subtilis (MIC = 0-0.3 
μg/disc), and the fungus Tricophyton mentagrophytes (MIC = 3.9-7.5 μg/disc). 
Further in vitro screening at the NCI showed that these compounds were 
selectively cytotoxic towards certain cell lines (Table 1.3); namely non-small cell 
lung (NCI-H23), melanoma (MALME-3M, M14, SK-MEL-5), and breast (MDA-
MB-435, MDA-N) (Table 1.4).68 However, when pterocellin A was selected for in 
vivo hollow fibre assay, it was found to be ineffective. As in vivo systems are 
complex, it is possible that pterocellin A was deactivated through metabolic 
processes. Interestingly, there are recent debates on the origin of the breast cancer 
cell line MDA-MB-435 and MDA-N used in the 60-cell line panel at the NCI. 
Gene expression studies have suggested that the breast cancer cell lines MDA-
MB-435 and its derivative MDA-N actually belong to the melanoma lineage and 
are related to the melanoma cell line M14.70-71 If this was indeed the case, then it 
would appear that pterocellins A and B are selectively cytotoxic towards 
(35) (36) 
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melanoma cell lines, as five of the six cell lines would belong to the melanoma 
family. 
Table 1.3 Panel average values for Pterocellins A and B from the 60-cell line panel screening 
at the NCI.68 
 GI50
a
 (μM) TGI
b (μM) LC50
c
 (μM) 
Pterocellin A 1.4 4.8 17.0 
Pterocellin B 0.7 2.1 6.9 
a growth inhibition; b total growth inhibition; c lethal concentration 
Table 1.4 Selective cell lines from the NCI 60-cell line panel, sensitive to the cytotoxicity of 
pterocellins A and B 
 GI50 (μM) TGI (μM) LC50 (μM) 
 A B A B A B 
Non-small cell lung cancer       
NCI-H23 0.3 0.1 1.0 0.3 6.1 0.7 
Melanoma       
MALME-3M 0.1 0.03 0.3 0.1 0.8 0.3 
M14 0.2 0.1 0.8 0.2 4.6 0.5 
SK-MEL-5 0.2 0.1 0.3 0.3 0.6 0.5 
Breast Cancer       
MDA-MB-435 0.2 0.2 0.3 0.3 0.6 0.6 
MDA-N 0.2 0.2 0.4 0.3 0.6 0.6 
 
There have been six pterocellin compounds published to date (A (35) – F (40)), 
another six proposed structures (G (41) – L (46)) are yet to be fully 
characterised.72 Unlike the potent pterocellins A and B, pterocellins C (37), E 
(39), F (40), H (42), I (43) possessed little or no activity against the P388 murine 
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leukaemia cell line. 69, 73 Pterocellin D (38) displayed moderate bioactivity activity 
against the same cell line with an IC50 value of 4773 ng/mL (Table 1.5).
69  
 
Table 1.5 Biological activity of Pterocellins A – I. 68-69, 74 
 
 
P388 
IC50 (ng/mL) 
Bsa 
MIC (μg/disc) 
Tmb 
MIC (μg/disc) 
(35) Pterocellin A 477 0-0.3 3.9-7.5 
(36) Pterocellin B 323 0-0.3 3.9-7.5 
(37) Pterocellin Cc >6250 0-0.5 NDd 
(38) Pterocellin D 4773 0.5-1 10-15 
(39) Pterocellin E >6250 0-0.5 ND 
(40) Pterocellin F >6250 0-0.5 ND 
(41) Pterocellin G Not yet tested   
(42) Pterocellin H >6250 ND ND 
(43) Pterocellin I >6250 ND ND 
a Bacillus subtilis; b Tricophyton mentagrophytes; c MIC values to be confirmed; 
d No activity observed. 
 
    
     
(37) (38) 
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(39) (40) 
(41) (42) 
(43) (44) 
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β-carboline alkaloids are commonly found in terrestrial plants, however their 
occurrence in the marine environment is uncommon.75 As well as the bioactive 
pterocellin alkaloids, a number of β-carboline alkaloids were also found in P. 
vesiculosa. In particular, 5-bromo-8-methoxy-1-methyl-β-carboline (47) was 
isolated from an extract collected from the Alderman Islands, New Zealand. It 
exhibited moderate cytotoxicity against the P388 murine leukaemia cell line with 
an IC50 value of 5089 ng/mL and also displayed antimicrobial and antifungal 
activities against the Gram-positive bacterium Bacillus subtilis (minimum 
inhibitory dose (MID) = 2-4 μg/mL) and the fungi Candida albicans (MIC = 4-5 
μg/mL) and Trichlophyton mentagrophytes (MIC = 4-5 μg/mL).76 Although β-
carboline alkaloids have been previously found in the same bryozoan family 
Catenicellidae, this was the first report of β-carboline alkaloids in the genus 
Pterocella.76 
  
 
(45) (46) 
(47) 
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Three species within the same bryozoan family: Costaticella hastata, 
Cribricellina cribraria, and Catenicella cribraria have also all produced β-
carboline alkaloids.  
 
(48) R1 = CH(OH)CH3; R2, R3 = H 
(49) R1 = CH3; R2, R3 = H 
(50) R1 = CH2CH3; R2, R3 = H 
(51) R1 = CHCH3; R2, R3 = H 
(52) R1 = CHCH3; R2 = OH; R3 = H 
 
The first β-carboline alkaloids from a bryozoan were isolated from Costaticella 
hastata. One of the isolated compounds, (S)-1-(1'-hydroxyethy1)-β-carboline (48), 
was a novel β-carboline metabolite. The other three were known β-carboline 
alkaloids previously isolated from terrestrial organisms.77 These were 1-methyl-β-
carboline (49) (also known as harman), 1-ethyl-β-carboline (50), and 1-vinyl-β-
carboline (51) (pavettine).77 Another β-carboline with vinyl substitution at the C1 
position was found in both Cribricellina cribraria and Catenicella cribraria.  
1-Vinyl-8-hydroxy-β-carboline (52) exhibited strong bioactivity against the P388 
murine leukaemia cell line. Both pavettine (51) and 1-vinyl-8-hydroxy-β-
carboline (52) had an IC50 value of 100 ng/mL.
75 1-Vinyl-8-hydroxy-β-carboline 
(52) was also screened against the 60-cell line panel at the NCI with panel average 
values of GI50 1.8 μM, TGI 5.8 μM, and LC50 19 μM.78 It was suggested that the 
vinyl substitution at C-1 was important for cytotoxicity as the other β-carboline 
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alkaloids, harman (49) and 1-ethyl- β-carboline (50) did not exhibit a high level of 
bioactivity against the P388 cell line in comparison.75  
 
 
1.4 Cell Death: Apoptosis and Necrosis 
Cell death is divided into two main forms: apoptosis and necrosis. Cell death is an 
essential part of normal development and tissue homeostasis in multicellular 
organisms.79 To maintain homeostasis and regeneration, there is a regulated 
balance between cell proliferation and cell death in all dividing cell populations. 
Cells that are lost during this normal turnover under physiological conditions are 
attributed to a process known as apoptosis. The term apoptosis originated in 1972 
when Kerr et al. described the observation of distinct morphological changes in 
cell death.80 Since this study, apoptosis remained one of the most investigated 
processes in biological research. 
 
1.4.1 Overview of Apoptosis 
Apoptosis is characterised by cell shrinkage, nuclear condensation, non-random 
DNA fragmentation, and membrane blebbing (protrusion of the plasma 
membrane) with no loss of membrane integrity. This targeted and regulated 
process retains the intracellular contents, therefore no inflammatory response is 
triggered.81 Just as mitosis is a significant process in cell proliferation, the role of 
apoptosis in normal physiology is just as important in regulating cell populations. 
As well as being important in physiological development, apoptosis can also 
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occur under pathological conditions. Alterations to the natural mechanisms of 
apoptosis can lead to many diseases such as neurodegenerative, autoimmune and 
cardiovascular diseases, and cancer.82-85  
Apoptosis is a critical defence mechanism against the formation and progression 
of cancer. Cancer cells are prone to resisting apoptosis, and one of the key 
mechanisms recognised in anticancer agents is the induction of apoptosis. 
Apoptosis can be initiated in response to a variety of stimuli via two distinct, but 
interconnected pathways: the extrinsic death receptor pathway and the intrinsic 
mitochondrial pathway (Figure 1.4).86 Both pathways converge on the same 
execution pathway involving a group of cysteine proteases known as ‘caspases’.87 
Caspases are responsible for the biochemical changes observed in apoptosis and 
are considered to be the executioner of apoptosis.86 In normal cells, caspases are 
found in an inactive form, expressed as a pro-enzyme. The proteolytic activities 
possessed by caspases are able to cleave substrates at highly conserved aspartic 
acid residues. This specificity is determined by the four residues amino-terminal 
to the cleavage site.86 The functions of caspases can be categorised into upstream 
initiator caspases (caspase-2, -8, -9, -10) and downstream effector caspases 
(caspase-3, -6, -7).87, 88 Effector caspases are activated proteolytically by upstream 
caspases, whereas initiator caspases are activated by regulated protein-protein 
interactions. This in turn triggers a cascade of signalling events in the 
commitment of apoptosis.89 It is still unclear what molecular mechanisms mediate 
the activation of initiator caspases; it is likely to be a more complex concept than 
understood currently.89 
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Figure 1.4 Apoptosis and caspase activation pathways (adapted from Reference 86).86 
 
 
Activation of initiator caspases by either extrinsic or intrinsic pathways will lead 
to biochemical modifications including DNA fragmentations, degradation and 
cross-linking of proteins, formation of apoptotic bodies, and expression of 
inward-facing phosphatidylserine groups on the cell surface for phagocytic 
recognition.87,90 The extrinsic death receptor pathway involves trans-membrane 
 (A). The extrinsic pathway is activated when a specific ligand binds to the death receptor, 
inducing the formation of DISC and triggering the caspase signaling cascade. (B). BID protein 
provides ‘cross-talk’ between the death receptor and mitochondrial pathway, promoting the 
release of cytochrome c from the mitochondria. (C). The intrinsic pathway is initiated by the 
release of cytochrome c from the mitochondria in response to various stimuli. Cytochrome c 
binds to Apaf-1 and promotes the recruitment of procaspase-9, forming an ‘apoptosome’ and 
activates caspase-9, which proceeds to activate caspase-3. 
A 
B 
C 
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receptor-mediated interactions with members of the tumour necrosis factor (TNF) 
receptor gene superfamily such as TNFR1 and FasR receptors.87 Apoptosis is 
triggered when a specific ligand binds to the corresponding death receptors on the 
cell surface. This results in the recruitment of the adapter molecule Fas-associated 
death domain protein (FADD) and the oligomerisation of procaspase-8 monomers 
to form the death-inducing signalling complex (DISC). The formation of the 
DISC induces autoproteolytic activation of the inactive procaspase to active 
caspase-8, triggering the execution phase of apoptosis.87, 89 The intrinsic 
mitochondrial pathway can be initiated by a variety of receptor-independent 
stimuli such as free radicals, radiation, DNA damage, viral infections, and 
toxins.87 These stimuli result in the loss of mitochondrial transmembrane potential 
and subsequently two main groups of intermembrane space proteins are released 
into the cytosol. The first group consists of pro-apoptotic proteins such as 
cytochrome c (cyt c) and Smac/DIABLO (second mitochondria-derived cyt c) that 
can activate the caspase-dependent mitochondrial pathway.89 The binding of 
cytosolic cyt c to the apoptotic protease activating factor (Apaf-1) prompts the 
recruitment and oligomerisation of procaspases-9, leading to the activation of 
caspase-9. The formation of the complex cyt c/Apaf-1/caspase-9, also known as 
an “apoptosome”, proceeds to activate caspase-3 and caspase-7 in the execution 
phase of apoptosis.89 The second group of proteins released from the 
mitochondria at a later stage are the apoptosis inducing factor (AIF) and 
endonuclease G.87 These proteins translocate to the nucleus after release and 
promote nuclear condensation and DNA fragmentation independent of the caspase 
activities.89  
  
 
  
 
27 
The intrinsic caspase activation by cyt c release from the mitochondria is a highly 
regulated process mediated by the Bcl-2 family of anti-apoptotic and pro-
apoptotic proteins. The anti-apoptotic proteins include B-cell lymphoma protein 2 
(Bcl-2) and Bcl-2 related protein-long isoform (Bcl-XL), and the pro-apoptotic 
proteins include BAX, BAK, and BH3 interacting domain death agonist (BID) 
protein.87 There is a degree of ‘cross-talk’ between the apoptotic pathways and 
BID is considered to play an important role in this. The DISC complex in the 
extrinsic pathway can proteolytically activate BID by truncating the C-terminal 
fragment of BID (tBID), which then promotes cyt c release after translocation to 
the mitochondria.91 
Both extrinsic and intrinsic pathways end up at the final execution phase of 
apoptosis involving caspase -3, -6, -7 with caspase-3 being the most important.87  
Once activated, caspase-3 specifically activates the endonuclease caspase-
activated DNAse (CAD) that is complexed with its inhibitor, ICAD, in its native 
state. Cleavage of ICAD releases CAD, which leads to the degradation of DNA 
and chromatin condensation.87 Caspase-3 is also responsible for the dismantling 
of the cell into apoptotic bodies.87 
In the absence of phagocytosis in in vitro systems, apoptotic cells proceed to 
secondary necrosis which shares many features of primary necrosis such as loss of 
membrane integrity and leakage of cell contents.92 This becomes problematic 
when trying to distinguish the cell death mechanisms, however there are other 
biochemical parameters that can be explored to distinguish between apoptosis and 
primary necrosis.  
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One of the ways to discriminate between apoptosis and primary necrosis is to 
utilise the fluorescent stains annexin-v and propium iodide. Annexin-v is a Ca2+ 
dependent protein that can bind to the phosphatidylserine groups exposed on the 
cell surface in the early stages of apoptosis.93 Propium iodide (PI) is a dye that is 
able to bind to DNA when the integrity of the nucleus is compromised. Apoptotic 
cells can be analysed using flow fluorocytometry (FACS) and distinguished from 
primary necrosis if they are positively stained with annexin-v with negative PI 
stain. Secondary necrosis can be identified if a shift from PI- to PI+ signal was 
observed, whereas primary necrosis would show PI+ staining straight away.92  
Another method to distinguish between apoptotic cells in secondary necrosis and 
primary necrosis is the detection of activated caspase-3 and caspase-7 in the 
supernatant by Western blot. Since these proteins are activated at the onset of 
apoptosis, they become detectable upon disruption of the plasma membrane 
during secondary necrosis. Caspase activation is not characteristic of primary 
necrosis and therefore no activated caspases will be detected in the supernatant, 
instead procaspases-3 and -7 will be observed.92 
 
1.4.2 Overview of Necrosis 
In contrast to apoptosis, necrosis is a passive form of cell death often triggered by 
injury to the cell. For a long time, the term necrosis was used to describe non-
apoptotic and accidental cell death as a consequence of injury caused by 
ischaemia and extreme trauma in pathological conditions.94 Necrosis is 
characterised by cellular swelling (oncosis), vacuolisation of the cytoplasm, and 
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loss of membrane integrity. This results in the uncontrolled release of intracellular 
contents into the surrounding environment which subsequently provokes an 
inflammatory response.95  
Due to its accidental nature, it was thought that necrosis was an unregulated and 
uncontrolled process that occurred after cell damage beyond repair, however 
emerging evidence have showed that this may not be the case.96, 94  Necrotic cell 
death can be induced by ligand binding at specific receptors on the plasma 
membrane. It has been found that certain types of cell death that resemble the 
morphological changes of necrosis in fact have distinct signalling pathways. 
Cross-regulation can occur between the apoptotic and necrotic pathways and it 
has been suggested that necrosis is a default cell death pathway.97 A shift from 
apoptosis to necrosis can be observed when cells are unable to propagate the 
signalling cascade of apoptosis due to the inhibition of its effectors. This type of 
regulated non-apoptotic cell death has been termed programmed necrosis, 
specifically, necroptosis.98  
Necroptosis was first described in 2005 when a study by Degterev et al. 
demonstrated that TNF-α, an inducer of apoptosis, was capable of activating a 
non-apoptotic cell death in the presence of caspase inhibitors.99 Although 
activated by the same stimulus, the morphological changes of the latter form of 
cell death were consistent with those of necrosis, not apoptosis.99 Several 
mediators of the necroptotic pathway have since been identified involving the 
receptor-interacting protein kinases (RIPK) and the poly(ADP-ribose) 
polymerase. The complete processes are however not fully understood.100 
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Table 1.6 Differences between apoptosis and necrosis 
Cell Death Morphological Differences 
Apoptosis 
 Targets single cells 
 Membrane blebbing but maintains integrity of the membrane 
 Increased mitochondria membrane permeability, release of pro-
apoptotic proteins, and formation of apoptotic bodies 
 Chromatin condensation and non-random DNA fragmentation 
 Apoptotic bodies ingested by neighbouring phagocytes 
 No inflammatory response 
Necrosis 
 Less regulated than apoptosis 
 Affects neighbouring cells 
 Cell and organelle swelling and lysosomal leakage 
 Loss of membrane integrity 
 Random degradation of DNA 
 Contents leak into the surrounding environment 
 Triggers inflammatory response 
 
 
1.4.1 Apoptosis Studies of Marine Natural Products 
Marine natural products have become important sources in the discovery of 
antitumour drugs. Cytotoxic natural products that selectively target the apoptotic 
pathways of cancer cells are particularly of interest in the development of 
chemotherapeutic agents. There are limited numbers of cytotoxicity studies on 
marine bryozoan natural products. Therefore a small selection of apoptosis studies 
on natural products from other marine organisms is described here to demonstrate 
some approaches taken to investigate the mechanism of cell death.  
Mycalamide A (53) and pateamine (54) are natural products isolated from the 
marine sponges of the Mycale species collected from New Zealand.101 In the 
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preliminary screening, both compounds showed potent antiviral, antifungal and 
cytotoxic activities. Mycalamide A (53) and pateamine (54) were found to be 
apoptotic inducers as determined by visualised DNA fragmentation, annexin-v 
staining, and characteristic morphology changes in H441, LLC-PK1 and SY5Y 
cells such as membrane blebbing and nuclear fragmentation.101 The DNA 
fragmentation was more pronounced in LLC-PK1 and SY5Y cells than in H441 
cells, which illustrate the difference in susceptibility in DNA laddering effects 
despite the similarity in the MTT responses. The IC50 values calculated from the 
MTT data were: 0.51 (H441), 0.64 (LLC-PK1) and 0.5 (SY5Y) nM for 
mycalamide A (53); and 0.37 nM (H441), 0.76 nM (LLC-PK1), and 0.26 nM 
(SY5Y) for pateamine (54).101  
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Gliotoxin (55) is a natural product produced by the marine fungus Aspergillus sp. 
102 Cytotoxicity studies were carried out in HeLa and human chondrosarcoma 
(SW1353) cells and found that gliotoxin induced apoptosis in both cell lines. This 
was demonstrated by DAPI [4',6-diamidino-2-phenylindole] and annexin-v/PI 
double staining analysis, disruption of mitochondrial membrane potential, cyt c 
release, DNA fragmentation, nucleus fragmentation, and morphological changes. 
Apoptosis was further confirmed by the activation of the caspases-3, -8 and -9; as 
well as down-regulation of the anti-apoptotic protein Bcl-2 and up-regulation of 
the pro-apoptotic protein BAX. These results indicate that gliotoxin is an inducer 
of apoptosis via the intrinsic mitochondrial pathway.102 
 
 
Physcion (56) is an anthraquinone derivative isolated from the marine-derived 
fungus Microsporum sp.103  
 
 
Physcion induced apoptosis in HeLa cells as demonstrated by the expression of 
apoptotic proteins p53, p21, BAX, Bcl-2, caspase-3 and -9. The expression of the 
pro-apoptotic protein BAX was up-regulated after treatment with physcion as 
(55) 
(56) 
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determined by Western blot analysis, subsequently activating the caspase-3 
pathway; whilst the anti-apoptotic protein Bcl-2 was down-regulated. 
These studies shared a common perspective in their approach to determining the 
mechanism of cell death by investigating typical apoptotic markers such as 
changes in cell morphology, DNA fragmentation, intracellular markers and the 
expression of specific apoptotic proteins. 
 
1.5 Outline of This Study 
Pterocellin A is a potent antitumour agent isolated from the marine bryozoan P. 
vesiculosa. In vitro bioactivity screening at the NCI showed promising results, 
however when pterocellin A was selected for in vivo hollow fibre assay, it was 
found to be ineffective.68 To find out how pterocellin A is cytotoxic, the 
biochemical processes need to be understood so modification or derivatisation of 
the compound can be made to enhance its in vivo activity for clinical 
development. 
The aim of this study is to elucidate the mechanism of cytotoxicity of pterocellin 
A; and to develop a systematic bioactivity screening process to be utilised for 
future natural product research at the University of Waikato. The objectives are: 
(i) identify the pathway of cell death induced by pterocellin A by assessing the 
characteristic markers of apoptosis and necrosis; (ii) investigate bioactive 
compounds from bryozoan crude extracts; and (iii) utilising the crude extracts for 
bioassay development.  
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2. Detection of Apoptosis in HeLa Cells 
2.1 Introduction 
Cellular toxicity can be manifested as either necrotic or apoptotic cell death. To 
study the cytotoxic effects of pterocellin A on HeLa cells, characteristic markers 
of apoptosis and necrosis were examined using various biochemical techniques. 
One of the characteristics of apoptosis is the ability for cells to maintain plasma 
membrane integrity after death. This was investigated using [3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) and lactate 
dehydrogenase (LDH) biochemical assays, as well as using the trypan blue 
exclusion experiment. Distinct morphological changes characteristic of cells 
undergoing apoptosis were examined under the microscope and other markers 
such as caspase-3 activation and DNA fragmentation were also investigated. 
 
 
2.2 Results 
2.2.1 HeLa Cell Growth Curve 
To find out the growth rate of HeLa cells under standard incubation conditions, a 
growth curve was plotted.  The HeLa growth curve showed that the cells entered 
the exponential growth phase after two days, and the log phase is between day 
three to day six (Figure 2.1). From visual observations, cells reached 100% 
confluency at day six (Figure 2.2). This observation was consistent with the log 
phase plotted on the growth curve. 
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Figure 2.1 HeLa growth curve over 8 days.  
Graph showing the mean cell count ± S.E.M. N = 3. 
 
 
 
Figure 2.2 Corresponding images of HeLa cell growth curve over 8 days. 
(Photos taken on an inverted Nikon eclipse TS100 microscope 
at 100X magnification with a Nikon COOLPIX 4500 camera). 
 
2.2.2 Determining Optimal Cell Counts 
Preliminary MTT and LDH assays were carried out to determine the optimal 
number of cells to be used for each experiment. This ensured that each experiment 
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could be reproduced if performed under the same conditions. According to the 
Beer Lambert law, the absorbance of a solution is directly proportional to its 
concentration. Since the formazan product from the MTT assay was representative 
of cellular metabolic activities, the absorbance was plotted against cell densities to 
determine a linear working range for the MTT assay (Figure 2.3). From the graph, 
the linear working range for the MTT assay had a maximum cell count of 5x104 
cells before the relationship was no longer linear. 
 
Figure 2.3 Optimal range of HeLa cell count for MTT assays. 
 
A similar experiment was carried out for the LDH assay to determine its linear 
working range (Figure 2.4). It was found that the LDH assay had a much smaller 
linear range than the MTT assay and the maximum cell number was 1x104 cells. 
This number was determined to be the optimal cell count as it lay within the linear 
range of the MTT assay also. 
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Figure 2.4 Optimum range of HeLa cell count for LDH assays. 
 
2.2.3 Determining Experimental Conditions for Pterocellin A 
Before studying the effects of pterocellin A on HeLa cells, basic experimental 
information was needed. This information included experimental parameters such 
as the incubation time, concentration range, and the experimental set up. There 
was no prior knowledge of such information on the HeLa cell line as previous 
work on pterocellin A was carried out on the P388 murine leukaemia cell line.68 
Therefore, in order to study the effects of pterocellin A on HeLa cells, an 
experimental protocol was developed. The first approach was to determine the 
concentration range and incubation period.  
After 24 hours incubation, cells treated with pterocellin A at a concentration 
greater than 3125 ng/mL were all killed (Table 2.1). This was also the same for 48 
and 72 hours incubation. The student t-test was used to determine any statistical 
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significance; statistically significant results were labelled with ‘*’ (p<0.05) 
(Figure 2.5).  
 
Table 2.1 Inhibition (%) at 24, 48 and 72 hours relative to solvent control 
Concentration 
(ng/mL) 
Mean % Relative Inhibition  
(to Solvent Control) 
24 hrs 48 hrs 72 hrs 
Growth Control 7.52 2.81 9.29 
98 25.17 4.51 4.12 
195 43.52 12.42 -3.22 
391 47.09 15.92 -2.06 
781 47.35 16.24 3.96 
1563 78.52 60.50 83.44 
3125 99.74 99.56 93.64 
6250 99.96 99.84 99.50 
12500 100.17 100.39 99.55 
 
 
From this, it was decided that a 24-hour incubation period was sufficient for 
further work. The IC50 values for each 24, 48 and 72 hour incubation period were 
886, 1175, and 1425 ng/mL respectively. Interestingly the relative inhibition of 
cells treated with the lower concentrations decreased over this time which 
attributed to the higher IC50 values (Figure 2.5). This suggests the cells were able 
to recover and overcome the cytotoxic effects of pterocellin A after a period of 
time. The IC50 value of pterocellin A on HeLa cells of 886 ng/mL was within the 
same order of magnitude as the IC50 of P388 cell line (477 ng/mL). This indicated 
that pterocellin A was cytotoxic against HeLa cells and that it was a good 
candidate cell line for this study. 
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Figure 2.5 Pterocellin A toxicity against HeLa cells after 24, 48 and 72 hours treatment, MTT assay. 
Bar graph showing the mean ± S.E.M. * = p < 0.05. N = 3.  
 
2.2.4 Membrane Integrity 
Once the incubation time was chosen, an LDH assay was carried out to find out if 
the decrease in cell viability affected the plasma membrane integrity. A 
proportional increase in detected LDH to cell viability measured by MTT would 
suggest cell lysis upon death, and therefore a necrotic cell death. 
It was found that although the level of LDH increased with higher concentration, 
there were variations in the calculated relative inhibition (%) between LDH and 
MTT assays (Figure 2.6). For example, at the lower concentration of 781 ng/mL, 
the calculated inhibition relative to the solvent control for the MTT assay was 
30.10% (Table 2.2). However, the result for the LDH assay, calculated relative to 
the maximum release of LDH, was 2.41%.  
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Figure 2.6 Pterocellin A toxicity against HeLa cells after 24 hours treatment, MTT and LDH assay. 
Bar graph showing the mean ± S.E.M. * = p < 0.05. N = 6. 
 
Table 2.2 Relative Inhibition (%) by MTT and LDH assays relative to control. 
Concentration 
(ng/mL) 
Mean % Relative Inhibition 
(to solvent control) 
MTT LDH 
Growth Control -26.30 - 
98 -24.06 -8.38 
195 -17.12 -5.89 
391 3.09 -5.83 
781 30.10 2.41 
1563 92.82 37.60 
3125 99.97 56.28 
6250 99.92 78.76 
12500 99.94 90.66 
  
Further experiments were carried out with a lower concentration range (Table 
2.3). Based on the MTT assay, it was found that there was a steady increase in 
relative inhibition as the concentration increased, however the level of detected 
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LDH remained relatively low (Figure 2.7). All cells were killed at 2000 ng/mL 
after 24 hours and the amount of LDH released was 29.54%. 
 
 
Figure 2.7 Pterocellin A toxicity against HeLa cells at 24 hours treatment, MTT and LDH assays.  
Bar graph showing the mean ± S.E.M. * = p < 0.05. N (MTT) = 12; N (LDH) = 6. 
 
Table 2.3 Relative Inhibition (%) by MTT and LDH assays after 24 hours incubation. 
Concentration 
(ng/mL) 
Mean % Relative Inhibition 
(to solvent control) 
MTT LDH 
Growth Control -9.92 2.81 
16 -28.05 3.30 
31 -15.64 3.92 
63 -21.30 0.07 
125 -4.71 -5.19 
250 -1.31 8.94 
500 17.76 5.30 
1000 51.89 8.92 
2000 108.31 29.54 
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Time-course experiments at 3, 6 and 12 hours were carried out to determine the 
time at which the cytotoxic effects of pterocellin A began to affect HeLa cells. At 
the highest concentration (2000 ng/mL), cells started being affected after just 3 
hours (Table 2.4), with no detectable LDH release. Similar observations were 
made after 6 hours (Figure 2.8, Figure 2.9, Table 2.5).  
Table 2.4 Relative Inhibition (%) by MTT and LDH assays after 3 hours incubation. 
Concentration 
(ng/mL) 
Mean % Relative Inhibition 
(to solvent control) 
MTT LDH 
Growth Control -0.22 - 
16 -10.83 -10.79 
31 -14.01 -8.26 
63 -21.40 -13.45 
125 -14.91 -16.78 
250 -16.80 -17.98 
500 -12.36 -19.31 
1000 -5.10 -16.42 
2000 21.51 -14.25 
 
 
 
Figure 2.8 Pterocellin A toxicity against HeLa cells at 3 hours treatment, MTT and LDH assays.  
Bar graph showing the mean ± S.E.M. * = p < 0.05. N (MTT) = 9; N (LDH) = 3. 
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Figure 2.9 Pterocellin A toxicity against HeLa cells at 6 hours treatment, MTT and LDH assays. 
Bar graph showing the mean ± S.E.M. * = p < 0.05. N (MTT) = 9; N (LDH) = 6. 
 
Table 2.5 Relative Inhibition (%) by MTT and LDH assays after 6 hours incubation. 
Concentration 
(ng/mL) 
Mean % Relative Inhibition 
(to solvent control) 
MTT LDH 
Growth Control -18.51 - 
16 -11.12 1.25 
31 -9.07 0.65 
63 -17.93 1.40 
125 -20.13 -0.32 
250 -19.97 1.25 
500 -19.92 -1.25 
1000 -13.80 -2.18 
2000 60.14 -1.45 
 
 
It was found that after 12 hours, the relative inhibition of cells treated with 1000 
ng/mL was 39.39% while that of cells treated with 2000 ng/mL was 87.88% 
inhibition (Table 2.6). The level of LDH increased slightly at approximately 20% 
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at these concentrations, however it did not correlate with the relative inhibition 
values by MTT (Figure 2.10). 
 
Figure 2.10 Pterocellin A toxicity against HeLa cells at 12 hours treatment, MTT and LDH assays.  
Bar graph showing the mean ± S.E.M. * = p < 0.05. N (MTT) = 9; N (LDH) = 6. 
 
Table 2.6 Relative Inhibition (%) by MTT and LDH assays after 12 hours incubation. 
Concentration 
(ng/mL) 
Mean % Relative Inhibition 
(to solvent control) 
MTT LDH 
Growth Control -6.48 - 
16 -13.75 0.28 
31 -7.69 3.36 
63 -2.46 1.15 
125 -7.20 -0.21 
250 0.29 -0.01 
500 -1.15 -1.76 
1000 39.39 26.32 
2000 87.88 23.48 
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2.2.5 Trypan Blue Exclusion 
A basic trypan blue exclusion cell count can distinguish between dead and live 
cells. Stained cells observed under the microscope would indicate a cell with a 
compromised plasma membrane. A trypan blue exclusion cell count was carried 
out after treating cells with different concentrations of pterocellin A for 24 hours. 
The calculated results are shown in Table 2.7. It was found that no stained cells 
were observed after treatment. The cell number steadily decreased as the 
concentration of pterocellin A increased (Figure 2.11). 
Table 2.7 Trypan blue exclusion results and calculations 
Trypan blue 
Cell Count 
 Mean % Relative 
Viability 
 Mean % Stained 
(dead) Cells 24 hr Treatment 
Solvent Control 2.75E+05 100.00 0.00 
Growth Control 2.88E+05 111.67 0.00 
62.5 2.48E+05 91.67 0.00 
125 2.72E+05 103.53 0.60 
250 2.45E+05 94.57 0.00 
500 1.85E+05 71.45 0.81 
1000 9.17E+04 35.45 0.00 
2000 1.67E+03 0.56 0.00 
 
Figure 2.11 Trypan blue exclusion cell count after 24 hour treatment.  
Bar graph showing the mean ± S.E.M. N = 3.   
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2.2.6 Changes in Cell Morphology 
Changes in cell morphology were observed after treatment with pterocellin A. 
Figure 2.12 shows the images of cells treated by different concentrations of 
pterocellin A taken at the end of each incubation period. 
3 Hours 6 Hours 12 Hours 24 Hours 
 
Figure 2.12 Images of cells treated at different concentrations of pterocellin A at different times. 
(Photos taken at 200X magnification using an inverted Nikon eclipse TS100 
microscope with a Nikon COOLPIX 4500 camera.) 
 250 ng/mL 
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The morphology of the cells started to change after 6 hours of incubation from 
1000 ng/mL. At the highest concentration (2000 ng/mL), the changes in cell 
morphology were obvious. Compared to the normal cells which appeared 
elongated and had contact with neighbouring cells, cells treated with pterocellin A 
appeared to have lost the contact and became round. The nuclei became 
condensed and were no longer visible. Cells also appeared more three-
dimensional, and membrane blebbing, a characteristic of cells undergoing 
apoptosis could be seen. Some cells appeared to be ‘shrinking’ and apoptotic 
‘spikes’ were also observed. After 24 hours treatment, cells were completely 
detached.  
 
Figure 2.13 Changes in cell morphology after treatment with pterocellin A at 2000 ng/mL.  
Black arrows pointing at examples of apoptotic features. (Photos taken at 
200X magnification using an inverted Nikon eclipse TS100 microscope with 
a Nikon COOLPIX 4500 camera.) 
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The presence of apoptotic cells was evident when observed under differential 
interference contrast (DIC) of a confocal microscope. Figure 2.14 shows cells 
undergoing late stage apoptosis; the membrane blebbing is clearly visible. A 
series of time-lapse photos was taken of a single cell undergoing apoptosis. Each 
image shows the movement of the apoptotic blebs.   
 
 
Figure 2.14 DIC images of a single apoptotic cell from the same experiment.  
(A). 1. Growth control. 2. Cells treated at 1000ng/mL for 6 
hours. (B). 1-9. Timelapse images of membrane blebbing of a 
single cell undergoing apoptosis. (Photos were obtained from an 
Olympus FV1000 confocal microscope at 400X magnification.) 
1 
 
2 
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2.2.7 Changes in Mitochondria Morphology and Location 
To investigate the effects of pterocellin A on mitochondria, cells were stained 
with MitoTracker Red CMXRos and visualised by a laser confocal fluorescent 
microscope. MitoTracker Red CMXRos is a membrane-permeable fluorescent 
dye used to label mitochondria. It contains a mildly thiol-reactive chloromethyl 
moiety that reacts with thiol groups of the proteins in the mitochondria.104  
To determine the staining concentration, normal cells grown in a fluoro dish 
(WPI) were first stained with 100 nM MitoTracker Red CXRos, however non-
specific staining was observed. The cells were then stained with 50 nM 
MitoTracker Red CMXRos to achieve specific staining of the mitochondria only 
with no background staining.  
 
Figure 2.15 Changes in mitochondrial morphology after pterocellin A treatment at 1000ng/mL 
after 6 and 12 hours. 
(A). Mitochondria stained with 50nM MitoTracker Red CMXRos (Em. 599 nm). 
(B). Overlay of stained mitochondria and phase contrast images. Photos obtained 
from the Olympus FV1000 laser scanning confocal microscope at 400X 
magnification. 
A 
B 
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After treatment with pterocellin A (1000 ng/mL), the location of mitochondria re-
distributed from the cell cytoplasm to the peri-nuclear region after six hours. This 
localisation took place before any notable changes in cell morphology and cell 
death as shown in the overlay images. Compared to healthy mitochondria that 
have an elongated tubular formation, the mitochondria of treated cells appeared to 
be fragmented and ‘swollen’ or ‘grain-like’ (Figure 2.15). 
2.2.8 Caspase-3 Activation 
The activity of caspase-3 was measured by FITC fluorescent staining. The 
original manufacturer’s protocol was adapted and modified for adherent HeLa 
cells. The fold-increase calculation was based on blank-corrected samples. 
Although the change in fluorescence between control and treatment seemed 
minimal, the change was more noticeable after each sample was blank corrected. 
Cells treated with pterocellin A (at both 500 ng/mL and 1000 ng/mL) had an 
approximate 2.5-fold increase in caspase-3 activity compared to the control 
(Figure 2.16).  
 
Figure 2.16 Caspase-3 activity of treated cells compared to control.  
Bar graph showing the mean ± S.E.M. N = 6. 
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However due to the small sample size the results were not statistically significant 
with the p values greater than 0.05. Cells were also visualised under the 
fluorescent microscope with a FITC filter, however fluorescence in treated cells 
could not be observed. 
 
2.2.9 DNA Fragmentation Studies 
Many attempts were made to visualise any DNA fragmentation from apoptotic 
cells. The first attempt to extract genomic DNA using the TRIzol reagent 
according to the manufacturer’s protocol was unsuccessful and the quality of 
DNA was poor when measured on a NanoDrop 2000 spectrophotometer 
(NanoDrop). The NanoDrop measures the amount of DNA which has a peak 
absorbance at 260 nm; it can detect impurities such as phenol or protein 
contaminations which have peak absorbance at 270 nm and 280 nm respectively. 
The ideal ratio should be above 1.8, however the NanoDrop readings for the 
TRIzol extractions were very low, ranging from 1.48 to 1.69. This suggested 
either phenol or protein contamination in the sample. When the samples were 
analysed on an agarose gel, the DNA bands did not move beyond the well which 
suggested large molecules of proteins trapped in the wells of the agarose gel. 
Attempts to remove the contamination by a proteinase-K digest and re-
precipitation of the DNA were also unsuccessful.  
The second attempt was to extract DNA using the Quick-gDNA™ MiniPrep Kit 
(Zymo). The quality of DNA improved dramatically with improved NanoDrop 
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readings closer to the ideal ratio of 1.8. However, when the extracted DNA was 
visualised on a 2% agarose gel, no fragmentation could be seen (Figure 2.17).  
   
Figure 2.17 Genomic DNA visualised on a 2% agarose gel, run at 35 V for 4 hours.  
(A, B) DNA extracted at different treatment concentrations at various time 
points using the Quick-gDNA™ MiniPrep DNA Extraction Kit (Zymo). 
 
A positive control was included with cells treated with rotenone (2 µM), a known 
inducer of apoptosis in HeLa cells.105 However, no DNA laddering could be seen 
in this either. 
Another attempt was made to extract the genomic DNA from treated cells. The 
experiment was up-scaled by growing cells in a T-25 culture flask instead of a 6-
well plate. This was to ensure that a sufficient amount of DNA was extracted. 
Cells were treated with 2000 ng/mL pterocellin A for 3 and 6 hours, and 1000 
ng/mL for 24 hours. Another batch of cells was treated with rotenone (5 µM) and 
the DNA was extracted at each time point. One flask of cells was starved for 24 
hours, and grown in DMEM with no FBS. DNA was then extracted and visualised 
on an agarose gel (2% agarose, 35 V). Unfortunately, due to the pre-existing 
A B 
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loading dye in the DNA Suspension Buffer, NanoDrop readings could not be 
obtained even after blanking with the solution. A faint ladder was finally observed 
in Lane 3 (Figure 2.18, A) in cells treated with 2000 ng/mL pterocellin A for 6 
hours.  
  
Figure 2.18 Genomic DNA visualised on a 2% agarose gel, run at 35 V for 4 hours.  
(A, B). DNA extracted at different treatment concentrations at 
various time points using the Apoptotic DNA Ladder Detection Kit 
(Abcam). Red arrow in (A) showing faint laddering in lane 3. 
 
No laddering could be seen in other lanes, including the positive rotenone positive 
control. When the experiment was repeated again with an added 12-hour time 
point, the laddering effect could no longer be seen. 
In order to assess whether rotenone was the right candidate for a positive 
apoptosis control, images of each flask were taken before and after treatment to 
compare morphology changes between pterocellin A and rotenone treated cells. 
The changes in morphology of rotenone treated cells can be seen in Figure 2.19 
after 24 hours, and apoptotic bodies were also present.  
A B 
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Figure 2.19 Comparison of cell morphology between cells treated with pterocellin A and rotenone. 
(Photos taken at 200X magnification using an inverted Nikon eclipse TS100 
microscope with a Nikon COOLPIX 4500 camera.) 
 
MTT and LDH assays were also carried out to see if there was any loss in 
membrane integrity. It was found that cells maintained membrane integrity in 
rotenone treated cells. Cells treated with pterocellin A only had a slightly elevated 
level of LDH after all cells were killed, which was consistent with experiments 
mentioned in Section 2.2.4. It is interesting to note that the cytotoxicity of 
pterocellin A seems to be more potent than that of rotenone. This combined with 
the apoptotic cells observed after treatment indicated that rotenone was indeed an 
apoptotic inducer. However for unknown reasons, no DNA laddering was 
observed despite various attempts. 
 
24 Hours After (1000 ng/mL) 
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Figure 2.20 Pterocellin A and rotenone toxicity after 24 hours treatment by MTT and LDH. 
Bar graph showing the mean ± S.E.M. N = 3. 
 
2.3 Discussion  
The objective of this section of the study was to elucidate the mechanism of 
cytotoxicity induced by the antitumour metabolite pterocellin A against HeLa 
cells. In order to assess the mechanisms of cell death, a number of detection 
methods were utilised to determine whether the HeLa cells were undergoing 
apoptosis or necrosis in the presence of pterocellin A.  
A number of MTT and LDH assays were performed during this study. The MTT 
assay was used to determine the cell viability after treatment with pterocellin A. 
The MTT cell viability assay measures the reduction of MTT, a water-soluble 
tetrazolium dye, to insoluble formazan crystals. This reduction reaction is 
dependent on the activity of functioning cellular dehydrogenases in living cells, 
thus is an indicator of cell viability and mitochondria activity.106 The LDH assay 
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is a colorimetric assay that detects the loss of cell membrane integrity by 
measuring the release of cytosolic enzyme LDH into extracellular space upon cell 
lysis. Similar to the MTT assay, the LDH assay involves the enzymatic 
conversion of a tetrazolium salt, INT [2-(4-iodophenyl)-3-(4-nitrophenyl)-5-
phenyl-2H-tetrazolium chloride], into a water-soluble red formazan product. The 
amount of colour formation is proportional to the amount of cell lysis.92  
Initial experimental data showed that pterocellin A affected cell viability 
significantly (p<0.05) within 24 hours of treatment in HeLa cells. A longer 
treatment period did not increase the cytotoxicity, as 100% of the cells were no 
longer viable at concentrations above 3125 ng/mL. Interestingly, cells that 
survived the first 24 hours at the lower concentration range had lower relative 
inhibition values after 48 and 72 hours as demonstrated by the IC50 values. This 
suggests that the cells were able to proliferate and overcome the cytotoxic effects 
after the first 24 hours. It was not known how the cells had the ability to adapt and 
overcome the cytotoxicity after prolonged exposure; perhaps it could be due to an 
up-regulation in the expression of the multi-drug resistant gene and associated 
proteins such as P-glycoprotein.107 It would be interesting for future research to 
carry out dose-response studies on HeLa cells treated with low concentrations of 
pterocellin A and examine the expression of proteins associated with multi-drug 
resistance. 
The first evidence that suggested that the cells were undergoing apoptosis was 
demonstrated by the difference in the relative inhibition from the MTT and LDH 
assays. These assays showed that after 24 hours, all cells were killed at 2000 
ng/mL according to the MTT data and also by visual observation. However, the 
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LDH data showed only a small increase in the level of detected LDH. The 
elevated LDH was likely due to a process known as secondary necrosis which 
occurs when the apoptotic cells have died but were not eliminated.108 It would 
have been ideal to utilise annexin-v/PI staining by FACS in this project to 
distinguish between apoptosis and primary necrosis, however this was not done 
due to limited resources and time constraints. It would definitely be of interest in 
future cell death studies to utilise this method for detecting early stages of 
apoptosis. 
In order to investigate apoptosis, a timeline would need to be established to ensure 
the experiments were carried out at the right time. Time-course experiments of 
pterocellin A showed that changes in HeLa cells after exposure to pterocellin A 
were detectable in just over three hours. Although visually the cell morphology 
displayed no change, detectable changes were observed in the MTT data. Since 
MTT is also an indicator of mitochondrial function, this suggests that there was a 
degree of mitochondria impairment attributed to the cytotoxicity of pterocellin A. 
Elevated LDH release was only apparent after 12 hours treatment at 2000 ng/mL 
when the cells were almost 90% inhibited. This further suggests that secondary 
necrosis took place to some extent after the apoptotic cells had already died.  
The trypan blue exclusion experiment indicated that neighbouring cells were 
indeed taking up apoptotic cells after death as no cells were observed in the cell 
count, even after collecting supernatant during harvest. However, when observed 
under the microscope straight after treatment, cell debris could be seen floating in 
culture medium after 24 hours. These were just cell debris and not intact dead 
cells, as they did not show up during the trypan blue exclusion cell count. 
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Presence of cell debris indicated that some degree of cell lysis took place in the 
form of secondary necrosis after apoptotic cells have died. 
Further evidence of HeLa cells undergoing apoptosis after exposure to pterocellin 
A was the morphological changes observed. After six hours treatment at 2000 
ng/mL, it became obvious when observed under the microscope that cells were 
affected by the cytotoxicity. Treated cells were no longer attached to their 
neighbouring cells compared to the control, the nucleus was no longer visible and 
the cells also appeared to ‘shrink’. This shrinking was due to condensation of the 
nucleus, another character of apoptosis. Additionally, apoptotic spikes and 
membrane blebbing were also observed within six hours of treatment. Time-lapse 
images taken under DIC on a confocal laser microscope displayed movement of 
the apoptotic blebs as the cells underwent apoptosis.  
The MitoTracker staining of the mitochondria showed that the mitochondrial 
morphology changed after six hour of treatment. In healthy cells, the 
mitochondria appear elongated and filamentous; after exposure to pterocellin A, 
distinct changes were observed under a confocal laser microscope. Mitochondria 
are normally distributed throughout the cytoplasm, however it was found that the 
mitochondria redistributed from the cell periphery and localised around the 
nucleus after treatment with pterocellin A. This change took place before changes 
in cell morphology were observed.  The overlay images showed that at 1000 
ng/mL after six hours, the cells still appeared normal compared to the control, 
however changes in the mitochondria were obvious. This concentration was 
chosen for the ease of preparation and it was not too much higher than the IC50 
value of 886 ng/mL. The individual morphology of the mitochondria went from 
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an elongated and filamentous appearance to spherical and ‘swollen’; it can also be 
described as a thread-grain transition.109 These changes in the location and 
morphology of the mitochondria have been reported in the literature including in 
HeLa cells during UV-induced apoptosis and in pig kidney (PEK) cells after 
treatment with rotenone, an inhibitor of the respiratory complex I.109-113 It was 
also found that the thread-grain transition occurred after the release of cyt c from 
the mitochondria upon induction of apoptosis.110 These distinct morphological 
changes further supported the idea that pterocellin A was an inducer of apoptosis 
in HeLa cells.  
It is hypothesised that pterocellin A could be acting on the mitochondria via the 
intrinsic pathway, however due to the complex nature of the signalling cascades, it 
is not yet known how the compound enters the cell and which pathway it is 
interacting with. Out of all the pterocellins, only those with no substitution at 
position 8, such as pterocellins A and B, exerted the highest antitumour activity 
against P388 cells. It could be that the biological interaction of pterocellins is 
size-dependent. The backbone ring structure could be intercalating with DNA and 
prompting apoptosis. It is also possible that if pterocellin A is able to target and 
enter the mitochondria, the mitochondrial DNA (mtDNA) could be more 
susceptible to damage due to the lack of histone proteins that are normally present 
in nuclear DNA as regulatory proteins.114 However, until further information is 
available it is difficult to make such assumptions. Discussions on future research 
can be found in Chapter Five. 
Another piece of evidence supporting this was the activation of caspase-3 detected 
after treatment by pterocellin A in HeLa cells. Activated caspase-3 is only present 
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upon the induction of apoptosis. Upon treatment by pterocellin A, the level of 
activated caspase-3 increased by approximately two-fold. However due to time 
constraint the caspase-3 assay was only performed after 24 hours incubation. It 
would have been ideal to carry out the assay on a time-course like the MTT and 
LDH assays. 
Despite the other evidence pointing towards apoptosis as the mechanism of cell 
death, one of the most well-known characteristics of apoptosis, DNA 
fragmentation, could not be detected using 2% agarose gel-electrophoresis. DNA 
extractions were carried out after treatment on a time-course and a positive control 
of a known inducer of apoptosis, rotenone, was used in these experiment. 
Unfortunately, there was no success at visualising the laddering effect from DNA 
fragmentation. Different extraction methods were carried out as it was initially 
thought that using the spin-column DNA extraction kit (Zymo) might have 
washed away the small fragments of DNA. However even with the other 
extraction kit (Abcam), no obvious laddering could be seen. Interestingly, after 
many attempts to visualise the DNA ladder, a very faint ladder was observed after 
six hours treatment by pterocellin A at 2000 ng/mL only after over-exposure of 
the agarose gel. However this was only visible in one sample and not in the 
others, including the positive rotenone control. A repeat was carried out in an 
attempt to visualise this again but was not successful. It was unknown whether 
this was due to experimental errors, or whether there are some unknown 
underlying biochemical mechanisms affecting the detection of DNA 
fragmentation. Internucleosomal DNA fragmentation is a late event of apoptosis 
and has been found not to be essential in the execution of apoptosis. Furthermore, 
it has been found that difference cell types have different susceptibility to DNA 
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laddering despite similar responses in the cell viability assays so this could likely 
be the case in this study.95, 115-116  
The gathered evidence to now support the notion that pterocellin A is an inducer 
of apoptosis in HeLa cells. The presented evidence includes the retainment of 
plasma membrane integrity upon cell death, morphological changes such as 
nucleus condensation, formation of apoptotic bodies and membrane blebbing, 
mitochondria relocation and thread-grain transition and caspase activation.  
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3. Bioassay Development using MTT 
and LDH Assays 
3.1 Introduction 
For the purpose of drug discovery, bioactivity screening is an important aspect of 
natural products research. One of the aims of this project was to develop an in-
house bioassay screening system to be utilised alongside the isolation process as 
guidance. This would be useful in research of natural products at the University of 
Waikato as previous bioassay experiments were carried out elsewhere. Bioassays 
for natural products work previously performed at the University of Waikato were 
mostly tested against the murine leukaemia P388 cell line.  
The objective of this section of the study was to develop a bioassay using the 
human cervical cancer cell line, HeLa and to utilise the MTT and LDH 
biochemical assays to assess cell viability and to gather any useful information on 
the possible mechanism of cell death. These assays were used extensively in the 
study of the pure compound pterocellin A on HeLa cells, with the intention being 
to demonstrate if the same approach could be applied to relatively crude fractions 
in the isolation process. 
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3.2 Results 
3.2.1 Establishing Experimental Conditions 
Much of the bioassay development was focused on determining the experimental 
conditions of the biochemical assays using HeLa cells. It was important that the 
protocols for the MTT and LDH assays were reproducible and robust. The process 
of determining the ideal conditions for each assay was described in Chapter Two. 
 
3.2.2 MTT Bioassay: C18 Fractions 
A crude extract of P. vesiculosa was obtained by bulk extraction as described in 
Chapter Six. Fractions (AW1.115.2 – 14) from the P. vesiculosa crude extract 
separated by reversed phase C18 column chromatography were screened to find out 
if the bioactivity of the pterocellins could be detected in the early stages of the 
isolation process. The fractions were then subjected to LC-MS to see if the 
presence of pterocellin A corresponded to the activity observed from the bioassay. 
MTT assay was used as the endpoint measurement of cell viability. The bioassay 
was carried out on a 96-well plate in triplicate with a range of four concentrations 
for each fraction, 0.025, 0.05, 0.1 and 0.2 mg/mL. The incubation period was 24 
hours in standard incubation conditions. The results are shown in Figure 3.1 and 
Figure 3.2. The standard errors of the mean were calculated and the student t-test 
was used to determine any statistical significance. Statistically significant results 
were labelled with ‘*’ (p<0.05). Fractions AW1.115.5 and AW1.115.6 displayed 
statistically significant strong inhibitory effects at the highest concentration (0.2 
mg/mL). AW1.115.5 was able to kill 70.86% of the cells at 0.2 mg/mL relative to 
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the control and 99.97% of the cells were killed at 0.2 mg/mL in the fraction 
AW1.115.6.  
 
Figure 3.1 Bioassay (AW1.115.2 – 7) against HeLa cells at 24 hours treatment, MTT.  
Bar graph showing the mean ± S.E.M. * = p < 0.05 N = 3. 
 
 
Figure 3.2 Bioassay (AW1.115.8 – 14) against HeLa cells at 24 hours treatment, MTT. 
Bar graph showing the mean ± S.E.M. * = p < 0.05 N = 3. 
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were also statistically significant. The moderately high activity displayed by the 
fractions AW1.115.11 and AW1.115.12 at 0.2 mg/mL was unlikely due to 
bioactive compounds. The test solutions were found to have precipitated out of 
the culture media and an insoluble mass was found at the bottom of the wells. The 
inhibitory effects were likely due to shock as the cell monolayer was covered by 
this insoluble mass and could not proliferate. The IC50 values were high (>125000 
ng/mL) as these fractions were very crude. 
 
3.2.3 MTT and LDH Bioassays: LH-20 Fractions 
Based on the bioactivity, the metabolite composition and the amount of material 
available, fraction AW1.115.6 was chosen to be further separated by a size 
exclusion LH-20 column. Although pterocellins A and B were present in 
AW1.115.5 in higher quantities than in AW1.115.6, AW1.115.6 also contained a 
number of brominated β-carboline alkaloids as determined by LC-MS (Section 
4.2.2). The main purpose for the LH-20 column was to separate the pterocellin 
alkaloids and the β-carboline alkaloids to determine whether the activities were 
contributed to the pterocellin alkaloids, β-carboline compounds, or combinations 
of both. An LDH assay was also carried out alongside the MTT assay to detect 
any loss of membrane integrity and therefore give an indication of the mechanism 
of cell death. It was found that fractions AW1.140.7 – 10 displayed significantly 
strong activities against the HeLa cells as determined by the MTT assay.  
Figure 3.3 shows the endpoint of the MTT assay whereby purple formazan 
crystals were formed in viable cells. Visually, it is clear that the cells in 
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AW1.140.7 – 10 were affected by the cytotoxicity of the fractions. The wells at 
the highest concentration (0.1 mg/mL) of the four fractions were colourless, 
indicating that all the cells were killed at that concentration. The colour intensity 
directly correlates to the absorbance reading and therefore determines the cell 
viability. 
 
Figure 3.3 MTT assay plate layout showing the endpoint of the experiment. 
Each fraction was tested in triplicate in four concentrations; 
highest concentration on the left. 
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The calculated results were consistent with the visual observation of the MTT 
assay plate, with strong activity in fractions AW1.140.7 – 10 (Figure 3.4 and 
Figure 3.5).  
 
Figure 3.4 Bioassay (AW1.140.4 – 9) against HeLa cells at 24 hours treatment, MTT. 
Bar graph showing the mean ± S.E.M. * = p < 0.05 N = 3. 
 
Figure 3.5 Bioassay (AW1.140.10 – 15) against HeLa cells at 24 hours treatment, MTT. 
Bar graph showing the mean ± S.E.M. * = p < 0.05 N = 3. 
 
*
*
*
*
* * * *
-30.00
-10.00
10.00
30.00
50.00
70.00
90.00
110.00
0
.0
1
2
5
0
.0
2
5
0
.0
5
0
.1
0
.0
1
2
5
0
.0
2
5
0
.0
5
0
.1
0
.0
1
2
5
0
.0
2
5
0
.0
5
0
.1
0
.0
1
2
5
0
.0
2
5
0
.0
5
0
.1
0
.0
1
2
5
0
.0
2
5
0
.0
5
0
.1
0
.0
1
2
5
0
.0
2
5
0
.0
5
0
.1
AW1.140.4 AW1.140.5 AW1.140.6 AW1.140.7 AW1.140.8 AW1.140.9
%
 R
el
a
ti
v
e 
In
h
ib
it
io
n
Concentration (mg/mL)
*
*
*
* *
*
-20.00
0.00
20.00
40.00
60.00
80.00
100.00
120.00
0
.0
1
2
5
0
.0
2
5
0
.0
5
0
.1
0
.0
1
2
5
0
.0
2
5
0
.0
5
0
.1
0
.0
1
2
5
0
.0
2
5
0
.0
5
0
.1
0
.0
1
2
5
0
.0
2
5
0
.0
5
0
.1
0
.0
1
2
5
0
.0
2
5
0
.0
5
0
.1
0
.0
1
2
5
0
.0
2
5
0
.0
5
0
.1
AW1.140.10 AW1.140.11 AW1.140.12 AW1.140.13 AW1.140.14 AW1.140.15
%
 R
el
a
ti
v
e 
In
h
ib
it
io
n
Concentration (mg/mL)
  
 
  
 
68 
Fraction AW1.140.8 displayed the highest activity with an IC50 value of 0.0132 
mg/mL; all the cells were killed at 0.025 mg/mL. The IC50 values for the other 
three bioactive fractions are listed in Table 3.1. The observed ions corresponded 
with the presence of pterocellin alkaloids in these fractions (Section 4.2.3). 
Interestingly however, no known pterocellins were detected in the relatively 
bioactive fraction AW1.140.10 and the fractions that follow. 
Table 3.1 IC50 values of fractions AW1.140.7 – 10 
Fraction # HeLa IC50 (mg/mL) 
AW1.140.7 0.0557 
AW1.140.8 0.0132 
AW1.140.9 0.0940 
AW1.140.10 0.0211 
 
To gather information on the possible mechanism of cell death in the early stages 
of the screening process, an LDH assay was carried out simultaneously to the 
MTT assay. The LDH assay detects the release of cytosolic LDH from a cell after 
the loss of membrane integrity, a characteristic of necrotic cell death. The plate 
layout of the LDH assay is shown in Figure 3.6.  
Similar to the MTT assay, the intensity of the colour directly correlates to the 
absorbance readings. Three controls were used in this experiment: the growth 
control which accounted for the basal levels of LDH release; the maximum 
release control which represented the complete lysis of the cell and the maximum 
amount of LDH release; and culture medium control to account for the serum in 
the medium that can affect the absorbance readings.  
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As shown in Figure 3.6, the wells containing the maximum release control have a 
deeper red colour compared to the growth control with only basal level release of 
LDH. 
 
Figure 3.6 LDH assay plate layout showing the endpoint of the experiment. 
It was found that the results from the LDH assay showed similar patterns to the 
work described in Section 2.2.4 where the cell viability calculated from the LDH 
assay did not align with the results from the MTT assay. In the MTT assay, 100% 
of the cells were killed at the highest concentration in AW1.140.7 – 10. However, 
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in the LDH assay, the highest calculated value for loss of membrane integrity and 
therefore cell death, was 20.2% in AW1.140.8 (Figure 3.7 and Figure 3.8). The 
inhibition values for the selected fractions for each assay are compared and listed 
in Table 3.2. 
 
Figure 3.7 Bioassay (AW1.140.4 – 9) against HeLa cells at 24 hours treatment, LDH. 
Bar graph showing the mean ± S.E.M. * = p < 0.05 N = 3. 
 
Figure 3.8 Bioassay (AW1.140.10 – 15) against HeLa cells at 24 hours treatment, LDH. 
Bar graph showing the mean ± S.E.M. * = p < 0.05 N = 3. 
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Table 3.2 Inhibition (%) by MTT and LDH assays relative to the control in selected fractions 
Fraction # 
Concentrations 
(μg/mL) 
Mean % Relative Inhibition 
MTT Assay LDH Assay 
AW1.140.7 
12.5 17.7 0.8 
25 15.4 0.8 
50 34.9 -0.6 
100 100.3 15.8 
AW1.140.8 
12.5 23.9 -0.2 
25 99.1 11.1 
50 99.4 17.6 
100 99.1 20.2 
AW1.140.9 
12.5 11.4 -1.3 
25 9.0 -1.5 
50 10.3 0.9 
100 96.3 5.2 
AW1.140.10 
12.5 6.6 0.1 
25 34.9 -0.8 
50 48.5 -2.6 
100 100.2 17.3 
 
 
3.3 Discussion 
The objective of this section was to develop a bioassay screening system using 
HeLa cells and utilising MTT and LDH biochemical assays to guide the isolation 
process. The ideal experimental conditions for the MTT and LDH assays were 
established based on work described in Chapter Two. The idea was to use MTT 
and LDH assays simultaneously to detect any signs of necrotic cell death in crude 
fractions at the early stages of the isolation process. Any notable bioactivity 
would be useful in guiding the isolation of the bioactive compounds. The MTT 
assay measures the cell viability and also the mitochondrial activity of the cells 
and is commonly used in bioassay screening. The LDH assay is able to measure 
the release of LDH due to loss of membrane integrity caused by necrotic cell 
death. Necrotic cell death is an unwanted trait in drug discovery as it results in the 
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induction of an inflammatory response when cell contents are released into their 
surroundings. A high level of cell death with a corresponding low level of 
detected LDH would suggest cells are dying by apoptosis as the cell contents are 
retained after cell death. The approach taken to study pure compounds against 
HeLa cells as described in Chapter Two was applied to crude fractions and the 
bioassays performed successfully.  
The first bioassay was able to detect the known cytotoxic effects of presumably 
pterocellin A or B in HeLa cells, as these two compounds are the most bioactive 
of the group. Two relatively crude fractions AW1.115.5 and AW1.115.6 
displayed strong activities against HeLa cells with IC50 values of 148.6 mg/mL 
and.3 mg/mL respectively; and the corresponding pterocellins A and B ions were 
observed in the LC-MS spectra (Appendix 2.4 and Appendix 2.5). Examining the 
LC-MS spectra alone would not have predicted the bioactivity as both fractions 
contained an abundance of other peaks at higher quantities than pterocellin A. 
These peaks were attributed to pterocellins H and I and a number of brominated 
β-carboline related compounds (See Chapter Four).  
Even though pterocellins A and B were present in AW1.115.11, the high levels of 
relative inhibition observed in fractions AW1.115.11 and AW1.115.12 were likely 
due to the precipitation of the test solution smothering the cells underneath; this 
was possibly caused by the salts or sterols in the solution (Appendix 2.12).   
The second bioassay was carried out on fractions obtained from the LH-20 
column separation of AW1.115.6. This fraction was chosen due to the presence of 
both pterocellin alkaloids and β-carboline alkaloids. The objective was to 
determine whether the observed activity was due to the action of either group of 
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compounds or perhaps a combination of both. The presence of pterocellin 
alkaloids contributed to the cytotoxicity in three of the four most active fractions. 
The cytotoxicity was likely contributed to both pterocellins A and B. In 
AW1.140.7, the concentration of pterocellin A was higher than B according to the 
LC-MS data (Appendix 2.8). In AW1.140.8 and AW1.140.9, the concentration of 
pterocellin B was higher than pterocellin A. Pterocellins H and I were also present 
in these fractions, however previous work by Masters student Marisa Till.73 
showed that they were not bioactive and therefore it is assumed they did not 
contribute to the observed effects. The fourth bioactive fraction, AW1.140.10 
interestingly contained no traces of pterocellin alkaloids according to the LC-MS 
data. Instead a number of previously reported and unknown β-carboline 
compounds were observed (See Chapter Four). 
A LDH assay was carried out alongside the MTT assay in this experiment to 
detect any loss of membrane integrity. It was found that the calculated values of 
inhibition in the LDH assay did not correspond to the inhibition values in the 
MTT assay. This pattern is similar to the work on pure pterocellin A described in 
Chapter Two. The slight increase in LDH levels seen in the bioactive fractions 
were likely due to secondary necrosis of apoptotic cells as discussed in Chapter 
Two. This experiment showed that the LDH assay can be used with crude 
fractions and changes can be detected at this stage of the isolation process. 
One of the concerns with using crude fractions for bioassay was whether the salt 
and solvent contents would interfere with the assay performance. This was taken 
into consideration when evaluating the results, however no significant adverse 
effects were observed as demonstrated by the solvent control. Another matter of 
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concern was the solubility of the crude fractions. One must ensure that the 
samples are sufficiently dissolved in methanol, and also make sure that the final 
solvent concentration does not exceed 2% of the overall volume. The insoluble 
material observed in AW1.115.11 and AW1.115.12 was likely due to be sterols 
which are non-polar, as these were collected from DCM fractions. The bioassay 
preparations used MeOH to dissolve each sample. This use of polar solvent could 
explain the insoluble mass observed. This problem could be addressed by using a 
mixture of MeOH and small amount of DCM and also adjusting the solvent 
control using the same mixture. 
The bioassay itself was a time consuming process. The preparation process 
involved growing HeLa cells to the optimum log phase, preparing test solutions 
and dilutions, treating the cells for a period of 24 hours and carrying out 
biochemical assays. Due to this, it was decided that four concentrations of each 
fraction prepared by serial dilution were sufficient for the bioassay. However, this 
was problematic when calculating the IC50 value. Due to the lack of data points 
along the X-axis (concentration), some IC50 values could not be calculated. The 
development of the bioassay protocol used in this study is not complete but good 
progress has been made. There are improvements needed for future research and 
these recommendations are discussed in Chapter Five. 
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4. Investigation of bioactive metabolites 
from Pterocella vesiculosa 
4.1 Introduction 
In the process of developing the bioassay, a number of fractions of the P. 
vesiculosa crude extract were analysed to investigate the metabolite composition. 
The specimen used in this study was collected from the Alderman Islands, New 
Zealand. 
Fractions of interest were defined as those: that displayed statistically significant 
bioactivity from the developed bioassay; containing peaks with moderate to high 
relative signal intensity in the base peak chromatogram and with a retention time 
of 15 – 30 minutes.  
A number of unknown metabolites were observed; they were grouped into either 
the pterocellins or the β-carboline alkaloids based on thin layer chromatography 
(TLC), LC-MS, and UV analyses. Some peaks of interest have been previously 
reported, however they are yet to be isolated and characterised to confirm the 
structures.  
 
4.2 Results and Discussion 
4.2.1 Preparation of the Pterocella vesiculosa crude extract 
The crude extract (4.2 g) was prepared from the bulk extraction (MeOH:DCM 
(3:1)) of a P. vesiculosa sample (201 g) obtained from the Alderman Islands (See 
Chapter Six).  
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4.2.2 Reversed Phase Chromatography of the P. vesiculosa Crude Extract 
The crude extract was separated by reversed phase (C18) column chromatography 
and 15 fractions were collected (Figure 4.1). The solvent scheme and the mass of 
each fraction are listed in Table 4.1. 
 
   
 
 
Figure 4.1 Separation of the crude extract by reversed phase C18 column chromatography. 
(A). Elution of the early polar fractions with the distinctive red colour 
indicative of the pterocellins. (B). Elution of fractions in the non-polar 
region. (C). Fractions collected from the C18 column. 
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Table 4.1 C18 fractions of AW1.115 and the recorded dry mass 
Fraction # Solvent Mass (mg) 
1 H2O - 
2, 3, 4 H2O/MeOH (1:1) 682.3, 215.8, 161.7 
5 H2O/MeOH (3:7) 125.7 
6 H2O/MeOH (1:9) 223.0 
7, 8 MeOH 151.1, 131.1 
9 MeOH/DCM (9:1) 274.3 
10, 11,  MeOH/DCM (1:1) 33.7, 80.7 
12 DCM 130.7 
13 MeOH 2.4 
14 H2O/MeOH (1:1) 0.4 
15 H2O - 
 Total mass: 2.2 g 
The LC-MS spectra of the crude extract AW1.116 (Appendix 2.2) contained 
peaks of known pterocellin and β-carboline alkaloids that have been characterised 
previously (Table 4.2), as well as a number of related compounds that have been 
reported by previous Masters students Marisa Till and Aaron Anderson.73-74  
Separation of the crude extract by C18 reverse phase column chromatography 
resulted in two moderately active fractions (AW1.115.4, AW1.115.7) and two 
highly active fractions (AW1.115.5 – 6) against HeLa cells as described in 
Chapter Three.  
Fractions (AW1.115) were analysed by TLC and LC-MS focusing on the four 
bioactive fractions (AW1.115.4 – 7). TLC of the bioactive fractions (Figure 4.2) 
showed pink spots in each fraction with Rf values of ~ 0.7 that were UV active at 
254 nm; the pink spots indicated the presence of pterocellin-like metabolites. Two 
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other spots were present in AW1.115.6 – 7 and these were also visible at 312 nm; 
the Rf values were 0.75 and 0.85 respectively. 
 
Table 4.2 Previously characterised metabolites from P.vesiculosa in the crude extract 
Compounds 
Observed ions 
(m/z, [M+H]+) 
LC-MS retention 
time (minutes) 
Pterocellin A68 295  23.1 
Pterocellin B68 319  24.1 
Pterocellin F69 581  27.8 
Pterocellin H74 343 19.0 
Pterocellin I74 377 19.8 
5-Bromo-8-methoxy-1-
methyl-β-carboline76 
291/293 20.5 
 
 
   
Figure 4.2 TLC analysis and Rf values of the bioactive AW1.115 fractions 
  
 
 
  
 
Rf values 
0.67 
0.85 
0.75 
0.70 
0.61 
 
 
= 254 nm 
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The base peak chromatograms of AW1.115.4 and AW1.115.5 revealed significant 
quantities of m/z 343 and m/z 377 which corresponded to pterocellins H and I 
respectively. AW1.115.4 also contained a significant peak of an unknown ion 
with m/z 345, likely to be a pterocellin related compound due to its similarity in 
the UV spectrum with pterocellin H. The odd number of the mass to charge ratio 
(m/z = [M+H]+) is also indicative of an even number of nitrogens which is typical 
of the pterocellins. AW1.115.5 also contained the m/z 345 ion, as well as a 
number of other unknown ions with their UV spectra closely resembling to those 
of the known pterocellins (Figure 4.3).  
 
 
 
 
Figure 4.3 UV chromatograms of pterocellin alkaloids and related unknown compounds from the 
fractions AW1.115.4 – 5 
(a) = m/z 501 (b) = m/z 345 (c) = m/z 379 (d) = m/z 415 
 
Although the pterocellin alkaloids were present in AW1.115.6, the fraction that 
managed to kill ~100% of the cells at 0.2 mg/mL, there were also multiple 
brominated metabolites observed including the previously characterised 5-bromo-
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8-methoxy-1-methyl-β-carboline (Appendix 2.1). The two isotopes of bromine, 
79Br and 81Br, occur naturally at approximately 1:1 ratio. The isotope patterns 
observed were typical of monobrominated compounds, indicating these 
metabolites were likely to be related to the group of monobrominated β-carboline 
alkaloids. The moderately active AW1.115.7 only contained minor quantities of 
pterocellin alkaloids, however the brominated compounds observed in AW1.115.6 
were also present. 
 
Table 4.3 Significant ions observed in the bioactive fractions AW1.115.4 – 7 
Potential 
Compounds 
Observed 
ions (m/z) 
LC-MS retention 
time (minutes) 
Fractions containing the 
observed ions 
Pterocellin 
related 
metabolites 
345 18.1 
AW1.115.4, AW1.115.5, 
AW1.115.6, AW1.115.7 
352 21.2 AW1.115.4, AW1.115.5 
379 19.7 AW1.115.4, AW1.115.5 
415 17.6 
AW1.115.4, AW1.115.5, 
AW1.115.6 
449 18.6 AW1.115.6 
501 23.6 AW1.115.5 
199 18.0 AW1.115.6 
β-carboline 
related 
metabolites 
213 19.2 AW1.115.6 
261/263 20.3 AW1.115.6, AW1.115.7 
275/277 20.8 AW1.115.7 
277/279 19.4 AW1.115.6, AW1.115.7 
303/305 22.2 AW1.115.7 
305/307 20.1 AW1.115.7 
337/339 22.8 AW1.115.7 
 
Interestingly, based on the LC-MS spectra, AW1.115.5 contained four times the 
quantity of pterocellins A and B than AW1.115.6, however the bioassay data 
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showed that AW1.115.6 was slightly more bioactive. It was not known at this 
stage whether the bioactivity was solely attributed to pterocellins A and B, or 
whether the presence of the β-carboline alkaloids affected cell growth. These 
unknown brominated β-carboline alkaloids could possess bioactivities yet to be 
elucidated. Previously isolated 5-bromo-8-methoxy-1-methyl-β-carboline from P. 
vesiculosa was found to have moderate bioactivity with an IC50 value of 5089 
ng/mL.76 Another interesting observation was that pterocellins A and B were 
present in the later fractions (AW1.115.8 – 11) but that these fractions were not 
bioactive.  Questions were raised as to whether the pterocellins were responsible 
for the high activity in the earlier fractions. This led to further separation by LH-
20 size-exclusion column chromatography of the bioactive fraction AW1.115.6 
that contained a mixture of pterocellin and β-carboline compounds. 
4.2.3 Size Exclusion Chromatography of the Bioactive Fraction 
AW1.115.6 was fractionated into 19 fractions by LH-20 size exclusion column 
(Figure 4.4). Bioassay of these fractions resulted in four active fractions (Table 
4.4), AW1.140.7 – 10 as discussed in Chapter Three. 
 
Table 4.4 Bioactive fractions from the LH-20 size exclusion column. 
Fraction # Volume (mL) Mass (mg) 
AW1.140.7 50 2.2 
AW1.140.8 50 0.9 
AW1.140.9 50 2.2 
AW1.140.10 50 0.4 
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Figure 4.4 Dried fractions from the LH-20 size exclusion column 
TLC analyses were carried out on all fractions. The highly pigmented fractions 
AW1.140.5 – 6 had higher masses than most of the other fractions. These 
fractions were presumed to contain high quantities of pterocellins A and B due to 
the distinctive red colour. However, the typical red spot of the pterocellins with Rf 
~0.7 was not present on the TLC (Appendix 2.7). Instead, these fractions barely 
moved from the baseline of the TLC plate in solvent (EtOAc:MeOH, 5:1) which 
suggest they were quite polar. The LC-MS spectra showed that these fractions 
contained a mixture of metabolites of similar quantities with no significant peak, 
whichcould explain the lack of bioactivity observed in the bioassay despite the 
presence of pterocellins A and B.  
In contrast, the fractions that displayed strong bioactivity did not have a large 
mass which could be due to the fractions being purer than the others. TLC 
analysis of the bioactive fractions showed a number of spots that were UV active 
at 254 nm and 312 nm. Although these fractions were not entirely pure, the 
distinct red spots of the pterocellins A and B at Rf  ~0.7 were visible on the TLC 
plate (Figure 4.5).  
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A B C 
 
Figure 4.5 TLC analysis of the bioactive fractions AW1.140.7 – 10. 
(A). TLC plate in normal lighting. (B). TLC plate at 254 nm. (C). TLC plate at 312 nm. 
 
Another interesting observation from the TLC analysis was that the yellow spots 
at Rf ~0.5 and the colourless spots around Rf ~0.8 appeared to fluoresce at 312 nm 
in fractions AW1.140.9 and AW1.140.10; these were characteristics of the β-
carboline alkaloids. 
Dereplication of known bryozoan metabolites was carried out on the LC-MS data 
of the bioactive fractions to separate known and unknown metabolites (Table 4.5). 
LC-MS analysis indicated that the separation of the pterocellins and the β-
carboline alkaloids was mostly successful. A noticeable quantity of pterocellin B 
was present in AW1.140.9 but no pterocellins were detected in the fractions 
following. A number of unknown ions were interest after analysing the LC-MS 
and bioassay data. These include pterocellin-related ions observed in the C18 
fractionation and the multiple numbers of monobrominated compounds likely to 
be related to the β-carboline alkaloids due to their similarity in the UV spectra. A 
Rf ~0.7 
Rf ~0.5 
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list of significant ions observed in the bioactive fractions can be found in Table 
4.6. 
Table 4.5 Dereplication of the bioactive fractions AW1.140.7 – 10 
Compounds 
Observed ions 
(m/z, [M+H]+) 
Bioactive fractions containing the 
known compounds 
Pterocellin A 295  AW1.140.7, AW1.140.8,  
Pterocellin B 319  AW1.140.7, AW1.140.8, AW1.140.9 
Pterocellin F 581  AW1.140.7 
Pterocellin H 343 AW1.140.7 
Pterocellin I 377 AW1.140.7, AW1.140.8 
1-methyl-β-carboline 
(Harman) 
183 AW1.140.9, AW1.140.10 
5-Bromo-8-methoxy-
1-methyl-β-carboline 
291/293 Not present in the bioactive fractions, 
but present in AW1.140.11 – 12. 
 
 
Table 4.6 Significant ions observed in the bioactive fractions AW1.140.7 – 10 
Potential 
Compounds 
Observed 
ions (m/z) 
LC-MS retention 
time (minutes) 
Fractions containing the 
observed ions 
Pterocellin related 
metabolites 
359 24.8 AW1.140.8, AW1.140.9, 
389 28.3 AW1.140.8 
β-carboline related 
metabolites 
199 18.0 AW1.140.10 
213 19.3 AW1.140.9, AW1.140.10 
227 19.8 AW1.140.9, 
261/263 20.3 AW1.140.9, AW1.140.10 
275/277 20.8 AW1.140.10 
Unknown 
403/405 22.5 AW1.140.9, AW1.140.10 
415 17.8 AW1.140.7 
417/419 23.1 AW1.140.9, AW1.140.10 
449 19.1 AW1.140.8 
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Pterocellin alkaloids generally display a distinctive UV spectrum which assists in 
identifying any similar metabolites in the isolation process. From the above 
bioactive fractions, there were not many peaks with such a UV pattern. Two ions, 
m/z 359 and m/z 389 had prominent peaks in the LC-MS spectra. They also shared 
a similar UV pattern to the pterocellins, however they were not an identical 
match. It was not known whether these two ions are truly related to the pterocellin 
alkaloids (Figure 4.6).  
 
 
Figure 4.6 UV chromatograms of possible pterocellin alkaloids from fractions AW1.140.8 – 9 
(a) = m/z 359 (b) = m/z 389 
 
A number of β-carboline-related metabolites were observed in the bioactive 
fractions AW1.140.9 – 10. These were confirmed by comparing the UV 
chromatograms to a known compound, the previously characterised 5-bromo-8-
methoxy-1-methyl-β-carboline (Figure 4.7). It is not known what the quantities of 
the brominated β-carboline alkaloids are, as brominated compounds are easily 
ionised and may give intense peaks even at low concentration. AW1.140.9 
contained a large amount of the known metabolite 1-methyl-β-carboline (49) 
(harman). This could have contributed to the activity observed. However it was 
previously found that harman was not bioactive against the P388 cell line. It is not 
known if harman is bioactive against HeLa cells. 
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Figure 4.7 UV chromatograms of as before possible β-carboline alkaloids from fractions 
AW1.140.9 – 10 
(a) = m/z 199 (b) = m/z 227 (c) = m/z 261/263 (d) = m/z 275/277 
 
The previously observed ions m/z 277/279, 303/305, 305/307 and 337/339 from 
the bioactive C18 fractionation were not observed in these bioactive LH-20 
fractions which suggests they were not representative of biologically active 
compounds. 
Due to time constraints of the project, further analyses of these fractions were not 
carried out. Although the scope of the project was not solely focused on the 
surveying of natural products, it would have been ideal to perform additional 
analyses such as tandem mass spectrometry and NMR spectroscopy on these 
fractions to obtain structural information. However, most of these observed ions 
have been reported previously, so an attempt was made to hypothesise the 
corresponding structures based on current knowledge. 
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Figure 4.8 Proposed corresponding structures.73  
The m/z 199 ion is 31 Da more than that of the β-carboline nucleus (168 Da). This 
could correspond to a methoxy substitution on the β-carboline core structure. If 
this were a methoxy-β-carboline alkaloid, then the tandem mass spectra would 
show a fragment of 15 Da from the loss of the methyl group. The m/z 227 ion 
could either correspond to an ethyl-methoxy-β-carboline or a propyl-hydroxy-β-
carboline alkaloid. It was previously reported by Aaron Anderson that the tandem 
mass spectra did not show a fragmentation of 15 Da, which would be 
characteristic of a methoxy substituent. Therefore this was likely to be the 
previously noted 7-hydroxy-1-propyl-β-carboline (Figure 4.8, a).73 The m/z 
261/263 ion could correspond to the demethoxy- counterpart (Figure 4.8, b) of the 
5-bromo-8-methoxy-1-methyl-β-carboline with a mass difference of 31 Da. The 
final unknown ion from the bioactive fractions m/z 275/277 is likely to be the 
previously reported 7-bromo-1-ethyl-β-carboline (Figure 4.8, c).73 
(a) m/z 227 (b) = m/z 261/163 
(c) = m/z 275/277 
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5. Concluding Remarks and Future 
Directions  
5.1 Concluding Remarks 
This project investigated the mechanism of cytotoxicity of pterocellin A against 
HeLa cells. Pterocellin A exhibited similar cytotoxicity against HeLa cells with an 
IC50 value of 886 ng/mL compared to the published IC50 value against P388 cells 
of 477 ng/mL. In this study, HeLa cells were incubated with up to 2000 ng/mL of 
pure pterocellin A and characteristic markers of apoptotic and necrotic cell death 
were assessed using several in vitro biochemistry techniques. The results from the 
time-course MTT and LDH assays showed only a low level of cytosolic LDH was 
detected in the supernatant after all the cells have died from pterocellin A at 2000 
ng/mL. This indicated the cells maintained plasma membrane integrity upon cell 
death suggesting apoptotic cell death. The slight increase in LDH levels after all 
the cells were killed was likely due to secondary necrosis, the final stage of 
apoptosis when phagocytes are absent. Additionally, morphological changes were 
observed after six hours of treatment at 2000 ng/mL. Cell shrinkage and nucleus 
condensation were observed, as well as apparent membrane blebbing, a key 
feature of apoptosis. The MTT data was also indicative of mitochondria 
impairment as the conversion of MTT to formazan relied on active mitochondrial 
dehydrogenases, suggesting that pterocellin A could be targeting the 
mitochondria. This hypothesis was supported by the observed changes in the 
morphology and location of the mitochondria after just six hours of exposure to 
pterocellin A at 1000 ng/mL; thread-grain transition of the mitochondria were 
observed. Furthermore, these changes to the mitochondria occurred before the 
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changes in cell morphology were observed. Although no DNA fragmentation was 
readily observed, the level of activated caspase-3 in HeLa cells increased after 
treatment with pterocellin A. Activated caspase-3 can only be detected after a 
series of signalling events following the induction of apoptosis. These data 
supported the notion that pterocellin A is an inducer of apoptosis in HeLa cells. 
This project also utilised biochemical assays and developed a systematic bioassay 
screening system at the University of Waikato, and further investigated the 
bioactive metabolites of P. vesiculosa. Although there are improvements that need 
to be implemented, good progress was made on the development of the bioassay 
system. The bioassays using HeLa cells and MTT/LDH assays were successfully 
carried out and demonstrated that the same approach taken to study pure 
compound in HeLa cells could be successfully applied to the bioassay 
development. Analysis of the bioactive fractions from the bioassay revealed 
several unknown metabolites that could be pterocellin alkaloids. It was not known 
which metabolite was responsible for the bioactivity shown in AW1.140.10 and 
further investigation is required in the future.  
 
5.2 Future Research  
There are still a number of areas of interest that remain unexplored and could 
form the basis of future research. To confirm that the mechanism of cell death is 
indeed attributed to apoptosis, additional information on apoptotic markers is 
required. These include the analysis of intracellular markers such as the release of 
cyt c from the mitochondria and other pro-apoptotic proteins assessed by Western 
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blot; DNA fragmentation using the PI stain analysed by FACS; and carrying out 
annexin-v staining to detect the presence of phosphatidylserine on the cell surface 
in the early stages of apoptosis. Since the MTT and MitoTracker data suggested 
impairment of the mitochondria after exposure to pterocellin A, other properties 
such as the disruption of the mitochondria membrane potential and an increased 
level of stress protein HSP60 could provide insight into the modes of action of 
pterocellin A. Although the findings from this study provided some good 
evidence that pterocellin A induces apoptosis in HeLa cells, the mechanisms for 
the initiation processes are not known. Some questions were raised during this 
study: how does pterocellin A enter a cell? What intracellular components is it 
targeting and interacting with? How is pterocellin A metabolised within the cell? 
Is the cytotoxicity activated by the parent compound or its metabolites? Perhaps 
future research could explore synthetic analogues of pterocellin A and determine 
the essential functional groups for cytotoxicity. Kinetic studies could also be 
explored to study the movement of pterocellin A into a cell. It would be 
interesting to investigate pterocellin A against human melanoma cells as the 
published data suggested that pterocellin A was selective cytotoxic against five 
melanoma cell lines. Future research could also explore the cytotoxicity of 
pterocellin A against non-cancerous cell lines to determine if the compound is 
selectively toxic to cancer cells. If found not to be cytotoxic, there could be great 
potential for pterocellin A as a lead compound for pharmaceutical development.  
Due to limited time associated with this project, a number of fractions of interest 
from P. vesiculosa were not explored further. Future research could include 
exploring the polar metabolites from the pterocellin fractions and identifying any 
further pterocellin alkaloids yet to be discovered. Another area of research to 
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pursue further would be the isolation and characterisation of the β-carboline 
alkaloids mentioned above to confirm the proposed structures. It would be 
interesting to find out which β-carboline metabolite was responsible for the strong 
bioactivity observed in the fraction that contained no pterocellins or the 5-bromo-
8-methoxy-1-methyl-β-carboline. 
The bioassay screening system developed in this study can be greatly improved in 
the future. Future work could include increasing data points for IC50 calculations 
and also to include a known positive control for each plate used in an experiment 
to eliminate errors. It is important for future improvements to develop a method 
that is robust, reproducible, and can be scaled for high throughput screening. 
Intra- and inter-assay variability should also be determined during future 
validations. Another recommendation for future research is to produce a flow-
chart protocol upon validated development of the bioassay system. This would 
ensure consistency across all the users of the bioassay system and therefore more 
precise data can be collected. 
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6. Materials and Methods 
6.1 Materials 
6.1.1 Commercial Kits 
6.1.1.1 CytoTox 96® Non-Radioactive Cytotoxicity Assay  
This kit was used to quantitatively measure lactate dehydrogenase (LDH), a stable 
cytosolic enzyme that is released upon cell lysis. The kit was supplied by 
Promega, Madison, Wisconsin, USA. The contents are listed in Table 6.1. 
Table 6.1 CytoTox 96® Non-Radioactive Cytotoxicity Assay Kit. 
Kit Contents 
Item Quantity 
Substrate Mix 5 vials 
Assay Buffer 60 mL 
LDH Positive Control 25 μL 
Lysis Solution (10X) 5 mL 
Stop Solution 65 mL 
 
6.1.1.2 Caspase-3 (active) FITC Staining Kit 
This fluorometric kit was used to measure caspase-3 activities in treated cells. The 
kit was supplied by Abcam, Cambridge, UK. The contents are listed in Table 6.2. 
Table 6.2 Caspase-3 (active) FITC Staining Kit 
Kit Contents 
Item Quantity 
FITC-DEVD-FMK  100 μL 
Wash Buffer 2 x 200 mL 
Z-VAD-FMK 10 μL 
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6.1.1.3 Apoptotic DNA Ladder Detection Kit 
This kit was used to isolate and detect any fragmentation of genomic DNA of 
treated cells. The supplier was Abcam, Cambridge, UK. The contents are listed in 
Table 6.3. 
Table 6.3 Apoptotic DNA Ladder Detection Kit 
Kit Contents 
Item Quantity 
Ammonium Acetate Solution 250 μL 
DNA Suspension Buffer 2 mL 
Enzyme A Solution 250 μL 
Enzyme B (Lyophilised) 1 vial 
TE Lysis Buffer  1.8 mL 
 
6.1.1.4 Quick-gDNA™ MiniPrep DNA Extraction Kit 
This kit was used to purify genomic DNA from cultured cells. The supplier was 
Zymo, Irvine, California, USA. The contents are listed in Table 6.4. 
Table 6.4 Quick-gDNA™ MiniPrep DNA Extraction Kit 
Kit Contents 
Item Quantity 
Genomic Lysis Buffer 50 mL 
DNA Pre-Wash Buffer 15 mL 
g-DNA Wash Buffer 50 mL 
DNA Elution Buffer 10 mL 
Zymo-Spin™ Columns 50 
Collection Tubes 100 
 
6.1.2 Common Solutions 
Table 6.5 lists the compositions of media, reagents and common solutions 
routinely used in the laboratory.  
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Table 6.5 Common Solutions Used in the Laboratory 
Solution Composition 
  
Complete DMEM 
(Dulbecco's Modified 
Eagle's Medium)  
0.5 mL penicillin/streptomycin (100X units total). 
5 mL foetal bovine serum (FBS). 
Make up to 50 mL in a Falcon tube with DMEM under 
sterile conditions. Store at 4°C. 
  
5% DMSO Freezing 
Media 
0.5 mL DMSO 
Make up to 10 mL in a Falcon tube with complete 
DMEM under sterile conditions. Store at 4°C protected 
from light. 
  
Phosphate Buffer 
Saline (PBS) 
8 g NaCl (137 mM)  
0.2 g KCl (2.7 mM)  
1.44 g Na2HPO4 (4.0 mM)  
0.24 g KH2PO4 (1.7 mM) 
Dissolve in 800 mL MilliQ water and adjust to pH 7, 
make up to 1 L, and store at 4°C. 
  
1 mg/mL Pterocellin A 
 
1.8 mg pterocellin A (crystallised – synthetic sample 
supplied by T. Ross Kelly, E. F. Merkert Chemistry 
Centre, Boston College, Chestnut Hill, Massachusetts, 
U.S.A.) 
Dissolved in 1.8 mL methanol and store at 4°C. 
  
5 mg/mL MTT 
Reagent 
 
0.01 g MTT 
Dissolve in 2 mL complete DMEM then filter through 
a 0.2 µm filter with a syringe. Mix well and store in 1 
mL aliquots protected from light. Store at 4°C for no 
more than 1 week.  
  
MTT Solubilising 
Solution 
 
1 mL HCl (1M) 
Make up to 10 mL with isopropanol. Store at 4°C. 
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1 μM MitoTracker 
Red CMXRos Stock 
Solution  
 
50 μg MitoTracker Red CMXRos 
Dissolve in 94 μL DMSO to make 1mM MitoTracker 
Red CMXRos. 
Take 10 μL of 1 mM MitoTracker and make up to 10 
mL with complete DMEM to make 1 μM solution. 
Store both solutions at -20°C. 
  
50 nM MitoTracker 
Red CMXRos 
Working Solution  
 
50 μL 1 μM MitoTracker. 
Make up to 1 mL with complete DMEM to make 50 
nM solution.  
Use immediately. 
  
0.5 M EDTA 14.61 g EDTA. 
Dissolve in 80 mL MilliQ water and adjust to pH 8. 
Make up to 100 mL. 
  
5X Tris-borate Buffer 
(TBE) 
54 g Tris base. 
27.5 g boric acid. 
20 mL 0.5 M EDTA. 
Make up to 1 L with MilliQ water. 
  
1X Tris-borate Buffer 
(TBE) 
200 mL 5X TBE buffer. 
Make up to 1 L with MilliQ water. 
  
6X Loading Buffer 0.5 mL glycerol. 
0.5 mL MilliQ water. 
50 μL 1% bromophenol blue. 
  
2% Agarose Gel in 1X 
TBE 
2 g agarose. 
Dissolve in 100 mL 1X TBE. 
Heat in microwave on high for 1 minute. 
Stir contents gently. 
Heat in microwave on high for another 30 seconds. 
Make up to 100 mL with 1X TBE. 
Add 2 drops (approximately 90 μL) ethidium bromide 
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Cool to 50°C and pour into casting tray, leave to set for 
30 minutes.  
For short term storage, cover gel in 1X TBE and store 
at 4°C. 
  
70% Ethanol 700 mL ethanol 
Make up to 1 L with MilliQ water 
  
1 mM Rotenone Stock 
Solution 
3.9 mg rotenone 
Dissolve in 10 mL DMSO, store at 4°C protected from 
light. 
 
6.1.3 Common Laboratory Chemicals and Reagents 
All water used in this project was deionised distilled water (≥ 18 MΩ-cm) purified 
on either an E-Pure (Barnstead) or a Direct-Q (Merck Millipore) ultrapure water 
system. Methanol and dichloromethane used in bench columns was distilled from 
drum grade before use. Common chemicals and reagents used and their sources are 
listed in Table 6.6. 
Table 6.6 Common Laboratory Chemical or Reagents  
Chemical or Reagent Source 
Trifluoroacetic acid  Acros Organics 
Boric acid 
Disodium hydrogen phosphate dodecahydrate 
Ethyl acetate 
Hydrochloric acid 
Potassium chloride 
Ajax  
Agarose LE AppliChem 
Ethylenediaminetetra-acetic acid (EDTA) 
Glycerol 
Sodium chloride 
BDH 
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Dichloromethane – drum grade Dongyue 
Isopropyl alcohol (IPA) – drum grade Exxon Mobil Chemical  
Dulbecco’s Modified Eagle Medium (DMEM): 
[+] High glucose (4.5 g/L) 
[+] L-glutamine 
[+] Phenol red 
[+] Sodium pyruvate; 
Foetal Bovine Serum (FBS) 
Penicillin-Streptomycin: 
- Penicillin 10000 U/mL 
- Streptomycin 10000 μg/mL 
Trypsin/EDTA 0.05% 
Gibco 
MitoTracker Red CMXRos 
SYBR® DNA Gel Stain 10000 X 
Invitrogen 
Acetonitrile – HPLC grade 
Methanol – drum grade 
Merck 
Bromophenol blue Park Scientific 
LH-20 (Sephadex) Pharmacia Fine Chemicals  
Methanol – HPLC grade 
Potassium dihydrogen phosphate 
Scharlau 
Rotenone 
Thiazolyl Blue Tetrazolium Bromide (MTT) 
Trypan Blue (0.4% w/v in PBS) 
Sigma 
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich 
DNA ladders (1 kb and 100 bp) Solis BioDyne 
Octadecyl Silane (C18) YMC 
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6.2 Methods 
6.2.1 Cell Culture 
Cell culture work was carried out under sterile conditions inside a laminar flow 
cabinet (Heraeus HERAsafe™) within a physical containment facility (PC2) at 
the University of Waikato. 
6.2.1.1 HeLa Cell Culture 
The human cervical cancer cell line, HeLa, was purchased from the American 
Tissue Culture Collection (ATCC) (Number CCL-2). The cells were grown in 
DMEM (25 mM D-Glucose, 4 mM L-Glutamine, 1 mM sodium pyruvate, Gibco) 
supplemented with 100X units of penicillin/streptomycin (Gibco) and 10% foetal 
bovine serum (FBS) (Gibco). Unless specified otherwise, cells were grown in T-
25 flasks (Biofil) in standard incubation conditions in a humidified incubator 
(Heraeus HERAcell™) at 37°C with 5% CO2. Cells were harvested and 
subcultured every four days at near confluency.  
To harvest, existing media was discarded and the adherent cell monolayer was 
gently washed with pre-warmed PBS (2 mL) before the addition of trypsin/EDTA 
(1 mL). This was followed by a short incubation period to aid the detachment of 
cells from the flask. Once the cells were in suspension, pre-warmed complete 
DMEM (4 mL) was added to neutralise the effects of trypsin. An aliquot was then 
taken for cell counting and the remaining cells were added to a new flask at a 
desirable seeding density with fresh complete DMEM. 
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6.2.1.2 Freezing Cells 
Cells were harvested as in Section 6.2.1.1 and centrifuged at 800 × g for five 
minutes. The supernatant was discarded and the cell pellet was re-suspended at a 
desirable cell density in freezing media, which consisted of complete DMEM with 
5% DMSO as cryoprotectant. The cell suspension was then divided into aliquots 
in cryogenic vials (NUNC) and placed in a CoolCell® (Biocision) freezing 
apparatus overnight at -80°C. The CoolCell® freezing apparatus allowed the cells 
to freeze slowly by steadily decreasing the temperature at approximately 1°C per 
minute. The next day, cryogenic vials were transferred to a storage container at -
80°C. 
6.2.1.3 Thawing Cells 
Cells were thawed quickly by placing the cryogenic vial in a 37°C water bath for 
one minute, then immediately transferred to a culture flask under sterile 
conditions. This was followed by the slow drop-wise addition of complete 
DMEM (4 mL) to the flask, and cells were left to recover overnight in standard 
incubation conditions. The media was changed the next day to remove traces of 
freezing media. 
6.2.1.4 Cell Counting 
Cell counts were carried out on a haemocytometer slide under the microscope at 
100X magnification. A mixture of cell suspension (10 µL) with an equal amount 
of Trypan Blue (Sigma) was added to the slide and covered with a glass coverslip. 
Cells in the four large outer corner squares were counted and the cell 
concentration was calculated with the following formula: 
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𝐶𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑚𝐿 =
𝐶𝑒𝑙𝑙 𝐶𝑜𝑢𝑛𝑡 𝑜𝑓 𝑂𝑢𝑡𝑒𝑟 𝐶𝑜𝑟𝑛𝑒𝑟𝑠
4
 ×  2 (𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝐹𝑎𝑐𝑡𝑜𝑟)  × 104 
Equation 6.1 Calculating cell concentration using a haemocytometer 
 
6.2.2 Biochemical Assays 
6.2.2.1 MTT Assay 
The Sigma thiazolyl blue tetrazolium bromide (MTT) reagent was used as per the 
manufacturer’s protocol. The MTT solution was freshly prepared before each 
experiment by dissolving in complete DMEM at a concentration of 5 mg/mL, pre-
warmed to 37°C and passed through a filter (0.2 µm) with a syringe. The 
solubilising solution was also freshly prepared to a final concentration of 0.1 M 
HCl in isopropanol.  
Each experiment was carried out in triplicate samples in 96-well cell culture plates 
(Biofil). There were three controls in each experiment: growth control, negative 
control and solvent control. Growth control consisted of untreated cells in media; 
solvent control consisted of untreated cells in media, with the addition of MeOH 
equal to the solvent percentage of the highest treatment concentration and the 
negative control consisted of media plus solvent. The final solvent concentration 
did not exceed 2% of the total volume. Near confluent cells in log-phase were 
harvested and seeded at a density of 1x104 cells per well, each well containing 
150 µL cell culture. The cells were then incubated at standard conditions 
overnight to allow the cells to attach and recover from handling before treatment 
was added. To carry out the assay, existing media containing test compound were 
removed and replaced with fresh media (150 µL per well). This was followed by 
the addition of reconstituted MTT in an amount equal to 10% of the media 
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volume (15 µL) and incubate at standard conditions for two hours. The MTT 
media was then carefully removed and replaced with MTT solubilising solution in 
an amount equal to the original volume (150 µL) to dissolve the formazan 
crystals. The samples were then placed on a plate-shaker (IKA® MS 1) for fifteen 
minutes at room temperature protected from light. Occasionally, some samples 
required mixing by pipette for homogenisation. Once homogenised, the samples 
were spectrophotometrically measured on a plate reader (Bio-Rad 680) at an 
absorbance wavelength of 570 nm, with a background absorbance reading at 655 
nm. Results were then blank corrected as per Equation 6.2.  
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 (𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑) =  (𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝐴𝑏𝑠)– (𝐵𝑙𝑎𝑛𝑘 𝐴𝑏𝑠) 
Equation 6.2 Blank correction for MTT assay 
Experimental values of relative growth inhibition were then calculated and expressed 
as percentage of solvent control, which is also indicative of mitochondrial 
dehydrogenase activity (Equation 6.3). 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 (%)
= 100% − 
𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 (𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑) ×  100%
𝑆𝑜𝑙𝑣𝑒𝑛𝑡 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 (𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑)
 
Equation 6.3 Relative growth inhibition calculations 
6.2.2.2 LDH Assay 
The LDH assays were carried out simultaneously to MTT assays using a CytoTox 
96® Non-Radioactive Cytotoxicity Assay commercial kit (Promega) as per the 
manufacturer’s protocol. The assay involved taking supernatant from treated cells 
without disturbing the cell population for MTT assay. The substrate mix used in 
the assay was reconstituted with assay buffer (12 mL) and stored at -20°C for no 
more than six to eight weeks protected from light. There were several controls 
included in these experiments: spontaneous release control (SRC), maximum 
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release control (MRC), and culture medium background control (CM). 
Spontaneous control corrected for the spontaneous release of LDH from cells; 
maximum control represented 100% release of LDH upon cell lysis and culture 
medium background control corrected for any LDH activity contributed by FBS 
in the DMEM, and the varying amounts of phenol red in the media. Cells were 
seeded as described in Section 6.2.2.1. The growth control from MTT assays 
served the same purpose as the spontaneous control in LDH assays.  
Cells were incubated with test compound as per experimental protocol. Prior to 
harvesting supernatant, 15 μL of lysis solution (10X) was added to the maximum 
release control. This allowed total cell lysis and therefore the release of total LDH 
into the supernatant. After incubating for forty-five minutes, the maximum release 
control was checked under the microscope to confirm complete lysis. The culture 
plate was then centrifuged (Heraeus™ Multifuge™ X3) at 250 × g at room 
temperature for four minutes to pellet any cell debris. 
To carry out the assay, 50 μL supernatant from each sample of the culture plate 
was transferred to a new assay plate (Greiner Bio-One). The reconstituted 
Substrate Mix was then brought to room temperature and 50 μL was added to 
each sample. This was incubated for thirty minutes at room temperature protected 
from light using foil, followed by the addition of Stop Solution (50 μL) to each 
sample. The samples were measured on a plate reader (Bio-Rad 680) at an 
absorbance of 490 nm within an hour of adding the stop solution. A syringe 
needle was used to remove any bubbles in the samples before measurements were 
taken. 
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To calculate the percentage of LDH release relative to the maximum release 
control (Equation 6.4), each set of data was blank corrected by subtracting the 
average of control background readings. The percentage of LDH release is also 
demonstrative of loss of membrane integrity due to necrotic cell death. 
𝐿𝑜𝑠𝑠 𝑜𝑓 𝑀𝑒𝑚𝑏𝑟𝑎𝑛𝑒 𝐼𝑛𝑡𝑒𝑔𝑟𝑖𝑡𝑦 (%) =  
𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 − 𝑆𝑅𝐶 
𝑀𝑅𝐶 − 𝑆𝑅𝐶
 ×  100 (%) 
Equation 6.4 Calculating loss of membrane integrity 
6.2.3 Statistical Analysis 
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐷𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 (𝜎) =  √
∑(𝑥 − ?̅?)2
𝑛 − 1
 
Σ = 𝑠𝑢𝑚 𝑜𝑓 
𝑥 = 𝑒𝑎𝑐ℎ 𝑠𝑎𝑚𝑝𝑙𝑒 𝑖𝑛 𝑡ℎ𝑒 𝑑𝑎𝑡𝑎 𝑠𝑒𝑡 
?̅? = 𝑚𝑒𝑎𝑛 𝑜𝑓 𝑎𝑙𝑙 𝑠𝑎𝑚𝑝𝑙𝑒𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑑𝑎𝑡𝑎 𝑠𝑒𝑡 
𝑛 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑑𝑎𝑡𝑎 𝑠𝑒𝑡 
Equation 6.5 Standard deviation calculation 
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐸𝑟𝑟𝑜𝑟 (𝑆𝐸) =
𝜎
√𝑛
 
σ = 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 
𝑛 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑑𝑎𝑡𝑎 𝑠𝑒𝑡 
Equation 6.6 Standard error calculation 
 
6.2.4 Work Described in Chapter Two 
All MTT assays mentioned in this chapter were carried out in triplicate in 96-well 
plates. LDH assays were always carried out simultaneously to the MTT assay. 
6.2.4.1 HeLa Cell Growth Curve 
The growth curve experiment was set up as shown in Figure 6.1. Each well was 
seeded with the same number of cells (2x104 in 1 mL) and grown for eight days 
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under standard incubation conditions. Media was changed after three days. At the 
same time each day, corresponding cells were harvested with PBS (100 μL), 
trypsin/EDTA (100 μL) and complete DMEM (900 μL). Cell count was carried 
out as described in Section 6.2.1.4 in triplicate per well to allow for any counting 
errors. The results were plotted on a graph to identify the log growth phase of 
HeLa cells. The calculated cell concentration (cells/mL) was equivalent to the 
number of cells in each sample with the volume being 1mL. 
 
Figure 6.1 Plate layout for the HeLa cell growth curve experiment 
6.2.4.2 Determining Optimal Cell Counts for MTT and LDH Assays 
In order to accurately quantify any changes in the rate of cell proliferation, a 
linear relationship between cell number and signal produced was established. For 
the MTT assay, cells were seeded at a range of densities (1x102, 5x102, 1x103, 
5x103, 1x104, 5x104, and 1x105 cells per 100 µL well) and left to attach overnight 
in standard incubation conditions. A blank containing no cells and only DMEM 
was also included. The MTT assay was carried out the next day as per the 
protocol described in Section 6.2.2.1. The absorbance was plotted against cell 
density and the linear region of the graph indicated the optimal cell counts for 
MTT experiments. The optimal cell count for the LDH assay was obtained in a 
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similar manner with cells seeded at 1x102, 5x102, 1x103, 5x103, 1x104, 5x104 and 
1x105 cells per 100 µL well). After the cells were attached overnight, 10 μL of 
10X lysis solution (1X) was added to each well and incubated for forty-five 
minutes under standard conditions. The plate was then centrifuged at 250 × g for 
four minutes at room temperature, and the LDH assay was carried out as per the 
protocol described in Section 6.2.2.2. 
6.2.4.3 Time-Course and Dose Response Experiment 
In order to obtain information on optimal experimental conditions, time course 
and dose response experiments were carried out. Following the suggestion of a 
generic protocol from previous bioassay work on the P388 cell line at the 
University of Canterbury, a 1 in 80 dilution (12500 ng/mL) of the pterocellin A 
stock solution (1 mg/mL) was prepared and a further seven concentrations were 
made by serial dilution (Table 6.7).  
 
Table 6.7 Pterocellin A concentrations used in initial time-course experiments 
Sample # Concentration (ng/mL) 
1 (lowest) 98 
2 195 
3 391 
4 781 
5 1563 
6 3125 
7 6250 
8 (highest) 12500 
Cells were seeded in triplicate as described in Section 6.2.2.1 and treatment of test 
compound was prepared by serial dilution (Figure 6.2) in the layout shown in 
  
 
  
 
106 
(Figure 6.3). This was incubated for initial time periods of 24, 48 and 72 hours. 
MTT and LDH assays were utilised at the end of each incubation period to 
measure cell viability and cell lysis (if any).  
 
 
Figure 6.2 Dilution series of the initial time-course dose response experiments 
 
 
Figure 6.3 Plate layout for MTT and LDH assays 
Further time-course and dose response experiments were carried out. Treatment 
with test compound was carried out at 3, 6, 12 and 24 hours with a much narrower 
range of concentrations (Table 6.8) prepared by serial dilution shown in Figure 
6.4. 
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Table 6.8 Pterocellin A concentrations used in later time-course experiments 
Sample # Concentration (ng/mL) 
1 (lowest) 16 
2 31 
3 63 
4 125 
5 250 
6 500 
7 1000 
8 (highest) 2000 
 
Figure 6.4 Dilution series of the later time-course dose response experiments 
 
6.2.4.4 Trypan Blue Exclusion Experiment 
This experiment was carried out in triplicate. Cells were seeded in a 24-well plate 
at 5x104 cells per well (100 μL) and left to attach overnight. Two controls were 
used in this experiment: growth control and solvent control. Six concentrations of 
pterocellin A treatment were prepared (Table 6.9) and cells were incubated in 
standard incubation conditions for 24 hours.  
To harvest the cells after treatment, culture media was transferred to Eppendorf 
tubes (1.5 mL) from each well to collect detached cells. The collected cells were 
then centrifuged at 800 × g for five minutes and the supernatant was removed. 
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While the collected cells were being centrifuged, those remaining were washed 
with pre-warmed PBS (0.5 mL) and harvested by adding trypsin/EDTA (0.2 mL). 
Table 6.9 Sample concentrations in trypan blue exclusion 
Sample # Concentration (ng/mL) 
Growth Control Cells + Media 
Solvent Control Cells + Media + MeOH 
1 (lowest) 62.5 
2 125 
3 250 
4 500 
5 1000 
6 (highest) 2000 
 
Once cells were in suspension, pre-warmed media (0.8 mL) was added to 
neutralise the effects of trypsin. This was then combined with the cells in 
Eppendorf tubes and cells were counted by trypan blue exclusion as an end point 
measurement. The numbers of excluded (live) cells and stained (dead) cells were 
recorded, and the cell viability relative to the solvent control was calculated. The 
calculated cell concentration (cells/mL) was equivalent to the number of cells in 
each sample with the volume being 1 mL. 
6.2.4.5 Caspase-3 Activation Assay 
This assay was carried out using a commercial kit Caspase-3 (active) FITC 
Staining Kit (Abcam) as per the manufacturer’s protocol with small 
modifications. Near confluent cells in log-phase were harvested and seeded at a 
density of 3x105 in a 6-well cell culture plate (Greiner Bio-One). The cells were 
then incubated at standard incubation conditions overnight to allow the cells to 
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attach and recover from handling before treatment was added. After treatment, the 
media from each well was transferred to Falcon tubes (15 mL) to collect any 
detached cells from treatment. The remaining cells were harvested by washing 
with pre-warmed PBS (1 mL) followed by the addition of trypsin/EDTA (0.5 
mL). Once detached, pre-warmed DMEM (1.5 mL) was added to each well to 
neutralise trypsin before being transferred to the corresponding Falcon tubes. An 
aliquot (100 μL) was then taken from each sample for a cell count. The remaining 
cells were centrifuged at 800 × g for five minutes, and the cell pellets were re-
suspended in pre-warmed DMEM (1 mL). To measure the fluorescent activity of 
caspase-3, FITC-DEVD-FMK (1 μL) was added to aliquots (300 μL) of each 
sample in Eppendorf tubes (1.5 mL) and incubated at standard incubation 
conditions for 1 hour. After incubation, the cells were centrifuged at 3000rpm for 
5 minutes and the supernatant was removed. Wash Buffer (0.5 mL) was then 
added followed by centrifugation; and this step was repeated again. Finally, the 
cell pellet was re-suspended in Wash Buffer (100 μL) then transferred to a black 
microtitre plate (Greiner Bio-One). The fluorescence intensity was measured on a 
plate reader (BMG Fluostar Optima) at excitation and emission wavelengths of 
485 nm and 520 nm respectively. 
6.2.4.6 Confocal Fluorescent Microscopy 
Fluorescent microscopy work was carried out on an Olympus FV1000 laser 
scanning confocal microscope. The staining and visualisation of the mitochondria 
utilised a fluorescent dye MitoTracker Red CMXRos which has peak absorption 
and emission at 578 nm and 599 nm respectively, producing a red fluorescence. 
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A stock solution (1 mM) was made up according to the manufacturer’s manual by 
adding DMSO (94 μL) to a vial (50 μg) of MitoTracker Red CMXRos at room 
temperature. An aliquot (10 μL) was made up to 1 μM with complete DMEM 
(9.99 mL) and stored at -20°C protected from light. The working solutions (50 
nM) were prepared fresh from the 1 μM stock solution before each experiment. 
To visualise mitochondria under fluorescence, cells were grown in a Fluorodish™ 
(WPI) and stained with working solution under standard conditions for twenty 
minutes. The staining media was then replaced with fresh media and cells were 
incubated for a further ten minutes to wash away unincorporated dye. Treatment 
of pterocellin A was applied after staining. 
6.2.4.7 DNA Extraction and DNA Agarose Gel Electrophoresis 
DNA extractions were carried out according to manufacturer’s protocol using 
either the Apoptotic DNA Ladder Detection Kit (Abcam) or the Quick-gDNA™ 
MiniPrep DNA Extraction Kit (Zymo). Cells were seeded in a 6-well plate 
(Greiner Bio-One) at 0.5 – 1x106 cells per well, and left to attach overnight and 
treatment was added the next day. 
DNA extraction using the Quick-gDNA™ MiniPrep DNA Extraction Kit (Zymo) 
was carried out as follows. Cells were harvested by directly adding the Genomic 
Lysis Buffer (1 mL) to each well after removing the media. This was then left for 
ten minutes at room temperature before being transferred to a Zymo-spin column 
in a collection tube. The column was then centrifuged at 10000 × g for one minute 
and the collection tube was discarded, and replaced with a new one. DNA Pre-
wash Buffer (200 μL) was added to the spin column and centrifuged again at 1000 
× g for one minute. This was followed by the addition of gDNA Wash Buffer 
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(500 μL) and further centrifugation. The collection tube was then discarded and 
the spin-column was placed in an Eppendorf tube with added Elution Buffer (150 
μL). This was incubated for five minutes at room temperature before 
centrifugation at 16000 × g for thirty seconds. The eluted DNA was then used for 
gel electrophoresis and the rest was frozen at -20°C. 
DNA extraction using the Apoptotic DNA Ladder Detection Kit (Abcam) was 
carried out as follows. Cells were harvested and pelleted as per normal; the 
supernatant was also collected to collect any detached cells. The cell pellet was 
washed by PBS and centrifuged at 500 × g for five minutes then the supernatant 
was removed. TE Lysis Buffer (35 μL) was then added and mixed by gentle 
pipetting to lyse the cells. This was followed by the addition of Enzyme A 
Solution (5 μL), gentle mixing by vortex and incubation at 37°C for twenty 
minutes. Enzyme B Solution (5 μL) was then added and cells incubated at 37°C 
for at least two hours. Afterwards, ammonium acetate solution (5 μL) was added 
to each sample, mixed, then followed by the addition of isopropanol (50 μL). This 
was kept in the freezer at -20°C overnight. Samples were centrifuged the next day 
for ten minutes at maximum speed (16000 × g) to precipitate the DNA. After 
removing the supernatant, the DNA pellets were washed with cold 70% ethanol 
(0.5 mL), and air-dried at room temperature for 10 minutes after the removal of 
ethanol. Finally, the pellet was dissolved in DNA Suspension Buffer (30 μL). 
To prepare for gel electrophoresis, 5 μL of each sample was mixed with a loading 
dye (2 μL) before being loaded into the gel. The gel was made by 2% agarose in 
1X TBE buffer, with a either small amount of ethidium bromide or SYBR Safe 
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Stain (Invitrogen). The gels ran at a low voltage (35V) for four hours before being 
analysed on the MiniBIS Pro using GelCapture software. 
 
6.2.5 Work Described in Chapter Three 
6.2.5.1 Bioassay Protocol Using the HeLa Cell Line 
Based on the biochemistry work carried out on pterocellin A using HeLa cells, a 
bioassay protocol was developed using MTT and LDH assays to guide the process 
of isolating bioactive natural products. The MTT and LDH assays followed the 
same protocol with the same controls as described in Section 6.2.2.1 and 6.2.2.2 
respectively. Bioassays were carried out in the PC2 laboratory using HeLa cells. 
Four concentrations were prepared from each fraction and the experiments were 
carried out in triplicate.  
The bioassay procedure for the C18 column fractions (AW1.115) was carried out 
as follows: a subsample (2 mg) was taken from each fraction (AW1.115.2 – 
AW1.115.14 and dissolved in MeOH to a stock concentration of 20 mg/mL. This 
was then further prepared into four working concentrations by serial dilution, and 
added to the corresponding wells on a 96-well plate containing 1x104 cells. The 
total dilution factor was 1:100. The final concentrations for the bioassay were 
0.025, 0.05, 0.1 and 0.2 mg/mL for each fraction. The plate was incubated in 
standard conditions for 24 hours and MTT assay was carried out at the end. The 
percentage of growth inhibition relative to the control was calculated using 
Equation 6.3.  
The bioassay procedure for the LH-20 column fractions (AW1.140) was similar to 
the above. Four concentrations in triplicate were assayed for each fraction. A 
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stock solution of each fraction (AW1.140.4 – AW1.140.15) was standardised to 
10 mg/mL. Final concentrations for the bioassay were 0.0125, 0.025, 0.05 and 0.1 
mg/mL. MTT and LDH assays were carried out at the end of the 24 hour 
incubation period. The percentage of growth inhibition relative to the control for 
both MTT and LDH assays was calculated using Equation 6.3 and Equation 6.4 
The IC50 values were calculated by plotting % inhibition vs. the logarithm of the 
sample concentration, and the antilog of the 50% value obtained was the IC50. An 
alternative method of obtaining the IC50 values was by plotting the log (% 
inhibition / (100 - % inhibition)) vs. log (concentration) and calculating the linear 
region of the regression line that intercepts the x-axis. This is a more precise way of 
obtaining the IC50 values, however it requires a high number of data points. 
 
6.2.6 Work Described in Chapter Four 
6.2.6.1 Bulk Sample Extraction 
Exhaustive bulk extraction was carried out on a proportion (201 g) of the P. 
vesiculosa (AI201-11, identified by sample voucher) sample. The extraction 
process began by soaking the sample in solvent (MeOH:DCM, 3:1) overnight at 
4°C. The sample was then blended in small quantities and filtered through a 
Buchner funnel to collect the filtrate. The dried sample was then repeatedly 
blended with fresh solvent (MeOH:DCM; 3:1) six times until the filtrate became 
colourless. The filtrate was then dried by rotary evaporation (Büchi) and 
lyophilisation in liquid nitrogen to yield crude extract AW1.116 (4.2 g). The crude 
extract was then subjected to further separation and analysis. 
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6.2.6.2 Thin Layer Chromatography (TLC) 
All fractions from each separation step were analysed by TLC using aluminium 
backed pates coated with silica gel (Merck TLC silica gel 60 F254). TLC analyses 
were performed in a solvent mixture of ethyl acetate and methanol 
(EtOAc:MeOH; 5:1). Samples were dissolved in MeOH and applied to the plate 
using thinly drawn glass capillary tubes. The TLC plates were then visualised 
under a UV lamp (Uvitec) at wavelengths of 245 nm and 312 nm. 
6.2.6.3 Reversed Phase C18 Column Chromatography 
The reversed phase column was prepared by mixing C18 gel (YMC) and MeOH to 
produce a slurry, which was then packed into a glass column and equilibrated 
back to H2O. The crude extract (AW1.111) was carefully loaded as solids and the 
chromatography followed a steep, stepped gradient from H2O to MeOH to DCM, 
then back to H2O (Table 6.10) under a gentle N2 gas pressure.  
Table 6.10 Solvent gradient for reverse phased chromatography 
Solvent Volume (mL) 
H2O 150 
H2O:MeOH (1:1) 335 
H2O:MeOH (3:7) 150 
H2O:MeOH (1:9) 150 
MeOH 300 
MeOH:DCM (9:1) 150 
MeOH:DCM (1:1) 160 
DCM 160 
MeOH 150 
H2O:MeOH (1:1) 150  
H2O  150 
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The collected fractions (AW1.115.1-15) were then rotary evaporated to dryness 
and transferred to a pre-weighed glass vial, which was then placed in a heating 
block (Lab-line) at 36°C to be dried under a gentle N2 stream. 
6.2.6.4 Size Exclusion Chromatography 
The size exclusion column was packed with Sephadex LH-20 (Pharmacia Fine 
Chemicals) into a glass column and eluted with MeOH. The sample (AW1.115.6) 
was loaded by dissolving in minimum MeOH and added to the column with a 
glass Pasteur pipette. Fractions (AW1.140.1-19) were collected (~ 50 mL each) 
and dried by rotary evaporation under N2. 
6.2.6.5 Liquid Chromatography – Mass Spectrometry (LC-MS) 
All LC-MS experimental data were generated on an HPLC (UltiMate 3000; 
Dionex) coupled to a mass spectrometer (Bruker Daltonics amaZon X™) using 
electrospray ionisation in positive ion mode. The instrumental method utilised a 
standard solvent gradient with running conditions listed in Table 6.11.  
All samples were prepared by dissolving in HPLC-grade MeOH (500 μL) and 
filtered (0.2 μm) into HPLC vials, followed by addition of MeOH (2 x 250 μL) 
into the vials. 
Table 6.11 LC instrumental conditions for all LC-MS experiments 
Flow Rate 0.2 mL/min 
Column 
Reversed Phase; Phenomenex, Luna 5 μ C18 100 Å, 150 x 
4.60 mm 
Column Temperature 25°C  
Mobile Phase Solvents 
Solvent A  
0.05% TFA in H2O 
Solvent B  
0.05% TFA in acetonitrile (ACN) 
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Detector  DIONEX UltiMate 3000 Diode Array Detector 
Run Time 50 minutes 
Gradient Programme 
 
Time (minutes) Solvent A % Solvent B % 
0 95 5 
2 95 5 
27 0 100 
39 0 100 
45 95 5 
50 95 5 
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Appendices 
Appendix 1: Bioassay Development Raw Data 
Appendix 1.1: AW1.115 Bioassay Raw Data, MTT Assay 
Appendix 1.2: AW1.140 Bioassay Raw Data, MTT Assay 
Appendix 1.3: AW1.140 Bioassay Raw Data, LDH Assay 
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Appendix 1.1: AW1.115 Bioassay Raw Data, MTT Assay 
Plate 1           
Sample # 
Crude 
Concentration 
(ug/ml) 
Mean 
RI% 
Standard 
Deviation 
RI% 
Standard 
Error RI% 
IC50 
(mg/mL) 
Growth 
Control 
0 -8.59 11.30 6.52   
AW1.115.2 
0.025 6.47 5.06 2.92 
0.4636 
0.05 -0.76 15.46 8.92 
0.1 -1.82 3.67 2.12 
0.2 6.97 2.61 1.51 
AW1.115.3 
0.025 9.45 13.55 7.82 
0.2194 
0.05 16.33 10.74 6.20 
0.1 16.38 8.60 4.97 
0.2 3.74 19.26 11.12 
AW1.115.4 
0.025 22.54 3.64 2.10 
0.2022 
0.05 26.03 19.37 11.19 
0.1 22.85 7.74 4.47 
0.2 32.50 11.54 6.66 
AW1.115.5 
0.025 11.78 8.73 5.04 
0.1486 
0.05 9.91 1.35 0.78 
0.1 16.63 5.78 3.34 
0.2 70.86 10.92 6.31 
AW1.115.6 
0.025 11.22 11.62 6.71 
0.1963 
0.05 6.37 27.38 15.81 
0.1 3.03 29.18 16.85 
0.2 99.97 0.30 0.18 
AW1.115.7 
0.025 45.39 7.23 4.18 
0.0229 
0.05 27.80 8.81 5.08 
0.1 22.74 8.04 4.64 
0.2 39.52 6.08 3.51 
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Appendix 1.1 (Cont.): AW1.115 Bioassay Raw Data, MTT Assay 
Plate 2           
Sample # 
Crude 
Concentration 
(mg/ml) 
Mean 
RI% 
Standard 
Deviation 
RI% 
Standard 
Error RI% 
IC50 
(mg/mL) 
Growth 
Control 
0 -15.17 13.43 7.76   
AW1.115.8 
0.025 5.87 3.01 1.74 
0.2728 
0.05 12.05 3.33 1.92 
0.1 6.54 4.22 2.43 
0.2 15.66 18.41 10.63 
AW1.115.9 
0.025 -7.67 9.96 5.75 
- 
0.05 -21.71 4.15 2.40 
0.1 -20.94 6.26 3.61 
0.2 -32.32 15.01 8.67 
AW1.115.10 
0.025 11.01 1.90 1.10 
- 
0.05 14.71 4.99 2.88 
0.1 8.08 4.64 2.68 
0.2 -5.15 13.73 7.93 
AW1.115.11 
0.025 -10.25 6.71 3.87 
0.1998 
0.05 -8.31 14.00 8.08 
0.1 -12.82 15.74 9.09 
0.2 36.33 29.80 17.20 
AW1.115.12 
0.025 -11.42 6.98 4.03 
0.1146 
0.05 -16.57 15.71 9.07 
0.1 -0.68 9.22 5.32 
0.2 74.84 26.28 15.17 
AW1.115.13 
0.025 12.37 12.07 6.97 
- 
0.05 -0.95 11.34 6.55 
0.1 -11.55 3.36 1.94 
0.2 -23.47 5.22 3.01 
AW1.115.14 
0.025 3.93 17.48 10.09 
- 
0.05 3.11 14.78 8.53 
0.1 16.61 14.43 8.33 
0.2 26.72 13.06 7.54 
            
  Plate 1 Plate 2 
  Mean 
Blanked 
Corrected 
Mean 
Blanked 
Corrected 
Solvent 
Control 
0.668 0.660 0.744 0.739 
Culture 
Medium 
(Blank) 
0.009 - 0.006 - 
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Appendix 1.2: AW1.140 Bioassay Raw Data, MTT Assay 
Plate 1           
Sample # 
Crude 
Concentration 
(mg/ml) 
Mean 
RI% 
Standard 
Deviation 
RI% 
Standard 
Error RI% 
IC50 
(mg/mL) 
Growth 
Control 
0 3.73 5.88 3.40   
AW1.140.4 
0.0125 1.22 6.62 3.82 
0.0502 
0.025 -1.22 2.89 1.67 
0.05 13.43 3.22 1.86 
0.1 28.15 4.83 2.79 
AW1.140.5 
0.0125 -7.71 4.91 2.84 
- 
0.025 -11.57 17.45 10.08 
0.05 -4.43 10.75 6.21 
0.1 -5.66 15.53 8.97 
AW1.140.6 
0.0125 5.91 4.55 2.62 
0.0635 
0.025 3.79 6.36 3.67 
0.05 5.33 4.94 2.85 
0.1 10.35 1.77 1.02 
AW1.140.7 
0.0125 17.67 16.07 9.28 
0.0557 
0.025 15.36 12.55 7.25 
0.05 34.96 5.89 3.40 
0.1 100.26 0.62 0.36 
AW1.140.8 
0.0125 23.91 9.35 5.40 
0.0132 
0.025 99.10 0.40 0.23 
0.05 99.42 0.19 0.11 
0.1 99.10 0.49 0.28 
AW1.140.9 
0.0125 11.38 9.13 5.27 
0.0940 
0.025 9.00 2.52 1.46 
0.05 10.28 16.07 9.28 
0.1 96.34 2.55 1.47 
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Appendix 1.2 (Cont.): AW1.140 Bioassay Raw Data, MTT Assay 
Plate 2           
Sample # 
Crude 
Concentration 
(mg/ml) 
Mean 
RI% 
Standard 
Deviation 
RI% 
Standard 
Error RI% 
IC50 
(mg/mL) 
Growth 
Control 
0 -3.28 2.39 1.38   
AW1.140.10 
0.0125 6.57 5.07 2.92 
0.0211 
0.025 34.88 4.35 2.51 
0.05 48.47 3.35 1.94 
0.1 100.16 0.34 0.20 
AW1.140.11 
0.0125 -10.84 1.09 0.63 
- 
0.025 -12.22 6.52 3.76 
0.05 -11.43 5.57 3.22 
0.1 -4.86 7.30 4.21 
AW1.140.12 
0.0125 21.41 15.73 9.08 
- 
0.025 1.31 19.00 10.97 
0.05 4.01 31.38 18.12 
0.1 -6.24 7.95 4.59 
AW1.140.13 
0.0125 -5.32 8.08 4.66 
- 
0.025 -5.65 11.28 6.51 
0.05 -0.20 7.74 4.47 
0.1 2.56 5.77 3.33 
AW1.140.14 
0.0125 -10.51 0.89 0.51 
- 
0.025 -11.30 4.95 2.86 
0.05 -4.47 11.03 6.37 
0.1 -6.63 18.33 10.58 
AW1.140.15 
0.0125 34.22 6.21 3.59 
- 
0.025 2.50 11.40 6.58 
0.05 -2.63 6.26 3.61 
0.1 -2.89 5.36 3.10 
 
     
      
 
Plate 1 Plate 2 
 
 
Mean 
Blanked 
Corrected 
Mean 
Blanked 
Corrected 
 Solvent 
Control 
0.528 0.519 0.515 0.508 
 Culture 
Medium 
(Blank) 
0.009 - 0.008 - 
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Appendix 1.3: AW1.140 Bioassay Raw Data, LDH Assay 
Plate 1         
Sample # 
Crude Concentration 
(mg/ml) 
Mean Membrane 
Integrity Loss % 
Standard 
Deviation 
% 
Standard 
Error % 
AW1.140.4 
0.0125 1.16 0.75 0.43 
0.025 1.14 0.99 0.57 
0.05 -0.60 0.33 0.19 
0.1 0.34 1.95 1.13 
AW1.140.5 
0.0125 0.16 0.38 0.22 
0.025 1.73 0.78 0.45 
0.05 2.20 1.43 0.82 
0.1 1.39 0.81 0.47 
AW1.140.6 
0.0125 -1.03 2.01 1.16 
0.025 0.00 2.52 1.46 
0.05 -0.04 2.52 1.45 
0.1 1.07 0.86 0.50 
AW1.140.7 
0.0125 0.78 1.45 0.83 
0.025 0.80 2.06 1.19 
0.05 -0.58 2.35 1.35 
0.1 15.81 3.46 2.00 
AW1.140.8 
0.0125 -0.20 0.27 0.16 
0.025 11.10 0.76 0.44 
0.05 17.58 2.49 1.44 
0.1 20.20 2.18 1.26 
AW1.140.9 
0.0125 -1.25 1.66 0.96 
0.025 -1.52 1.20 0.69 
0.05 0.90 0.08 0.05 
0.1 5.17 1.57 0.91 
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Appendix 1.3 (Cont.): AW1.140 Bioassay Raw Data, LDH Assay 
 
Plate 2         
Sample # 
Crude Concentration 
(mg/ml) 
Mean Membrane 
Integrity Loss % 
Standard 
Deviation 
% 
Standard % 
AW1.140.10 
0.0125 0.05 1.35 0.78 
0.025 -0.82 0.49 0.28 
0.05 -2.56 0.64 0.37 
0.1 17.29 0.49 0.28 
AW1.140.11 
0.0125 0.91 2.12 1.22 
0.025 0.11 3.26 1.88 
0.05 2.22 12.39 7.16 
0.1 1.37 0.30 0.18 
AW1.140.12 
0.0125 2.39 3.99 2.30 
0.025 1.90 1.99 1.15 
0.05 2.33 3.86 2.23 
0.1 -0.60 0.63 0.36 
AW1.140.13 
0.0125 -0.68 0.39 0.23 
0.025 0.11 0.79 0.46 
0.05 0.17 0.20 0.12 
0.1 1.24 0.67 0.39 
AW1.140.14 
0.0125 -0.49 0.93 0.54 
0.025 0.09 0.67 0.39 
0.05 -0.80 0.00 0.00 
0.1 -0.54 0.05 0.03 
AW1.140.15 
0.0125 -1.48 0.79 0.45 
0.025 -0.62 0.35 0.20 
0.05 -1.19 0.37 0.21 
0.1 -1.27 0.42 0.25 
 
        
 
Plate 1 Plate 2 
 
Mean Blanked Corrected Mean 
Blanked 
Corrected 
Spontaneous 
Release 
0.851 0.225 0.873 0.202 
Maximum 
Release 
2.695 2.069 3.032 2.361 
Culture 
Medium 
(Blank) 
0.626 - 0.671 - 
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Appendix 2: Analysis of Pterocella vesiculosa 
Appendix 2.1: LC-MS base peak chromatogram (BPC) of the P. vesiculosa 
crude extract 
Appendix 2.2:  BPC of the P. vesiculosa crude extract and mass spectra of 
known metabolites 
Appendix 2.3:  BPC of fraction AW1.115.4 and mass spectra of significant 
metabolites 
Appendix 2.4: BPC of fraction AW1.115.5 and mass spectra of significant 
metabolites 
Appendix 2.5: BPC of fraction AW1.115.6 and mass spectra of significant 
metabolites 
Appendix 2.6: BPC of fraction AW1.115.7 and mass spectra of significant 
metabolites 
Appendix 2.7: TLC analysis of the size-exclusion column fractions 
AW1.140.1– 19. 
Appendix 2.8: BPC of fraction AW1.140.7 and mass spectra of significant 
metabolites 
Appendix 2.9: BPC of fraction AW1.140.8 and mass spectra of significant 
metabolites 
Appendix 2.10: BPC of fraction AW1.140.9 and mass spectra of significant 
metabolites 
Appendix 2.11: BPC of fraction AW1.140.10 and mass spectra of significant 
metabolites 
Appendix 2.12: Separation tree for the Pterocella vesiculosa extract 
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Appendix 2.1: LC-MS base peak chromatogram (BPC) of the P. vesiculosa crude extract
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Appendix 2.2: BPC of the P. vesiculosa crude extract and mass spectra of known metabolites 
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Appendix 2.3: BPC of fraction AW1.115.4 and mass spectra of significant metabolites 
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Appendix 2.4: BPC of fraction AW1.115.5 and mass spectra of significant metabolites 
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Appendix 2.4 (cont.): BPC of fraction AW1.115.5 and mass spectra of significant metabolites 
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Appendix 2.5: BPC of fraction AW1.115.6 and mass spectra of significant metabolites 
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Appendix 2.5 (cont.): BPC of fraction AW1.115.6 and mass spectra of significant metabolites 
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Appendix 2.6: BPC of fraction AW1.115.7 and mass spectra of significant metabolites 
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Appendix 2.6 (cont.): BPC of fraction AW1.115.7 and mass spectra of significant metabolites 
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Appendix 2.7: TLC analysis of the size-exclusion column fractions AW1.140.1 – 19. 
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Appendix 2.8: BPC of fraction AW1.140.7 and mass spectra of significant metabolites 
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Appendix 2.9: BPC of fraction AW1.140.8 and mass spectra of significant metabolites 
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Appendix 2.10: BPC of fraction AW1.140.9 and mass spectra of significant metabolites 
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Appendix 2.11: BPC of fraction AW1.140.10 and mass spectra of significant metabolites 
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